Stockwinners Market Radar for October 03, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:12 EDT Cathie Wood's ARK Investment bought 148K shares of SomaLogic today

18:35 EDT Paychex CEO: The labor market is still tight - In an interview on CNBC's Mad Money, John Gibson said small to medium sized businesses continue to be resilient. Wage growth and inflation continues to cool with stable job growth, he added. There is a labor supply problem in finding high quality employees, he noted.

18:14 EDT Orchid Island Capital CEO buys $235.7K in common stock - In a regulatory filing, Orchid Island Capital disclosed that its CEO Robert Cauley bought 30K shares of common stock on October 3rd in a total transaction size of $235.7K. Shares of Orchid Island Capital are up 3.3% afterhours at $7.89.

18:07 EDT Vertex Pharmaceuticals reports data from Phase 1/2 clinical trial of VX-880 - Vertex Pharmaceuticals presented longer-term data on patients dosed in Parts A and B of its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy in people with type 1 diabetes, or T1D, with impaired hypoglycemic awareness and severe hypoglycemic events, or SHEs. Prior to VX-880 treatment, all six patients enrolled had long-standing T1D with no endogenous insulin secretion, required an average of 34.0 units of insulin per day, and had a history of recurrent severe hypoglycemic events in the year prior to screening. All patients in Part A and B now have more than 90 days of follow-up and have demonstrated islet cell engraftment and endogenous glucose-responsive insulin production on the Day 90 mixed-meal tolerance test, or MMTT. All patients demonstrated improved glycemic control across all measures, including decreases in HbA1c, improved time-in-range on continuous insulin monitoring, and reduction or elimination of exogenous insulin use. The two patients with at least 12 months of follow-up after VX-880 infusion, who were therefore evaluable for the study's primary efficacy endpoint, met the criteria for the primary endpoint of elimination of SHEs between Day 90 and Month 12 with an HbA1c less than7.0%. The first patient achieved insulin independence at Day 270 through Month 24. This is a patient who has had T1D for nearly 42 years and prior to trial enrollment was on 34 units of daily exogenous insulin. The second patient achieved insulin independence at Day 180 through Month 12. VX-880 has been generally well tolerated in all patients dosed to date. The majority of adverse events, or AEs, were mild or moderate, and there were no serious AEs related to VX-880 treatment. As previously reported, one subject had SHEs in the perioperative period. There have been no other SHEs in the study.

18:01 EDT CareDx 'respectfully disagrees' with Supreme Court decision in patent case - CareDx (CDNA) acknowledged the Supreme Court's decision not to review the Federal Circuit's decision on the patent eligibility of three Stanford-licensed patents. CareDx notes the decision does not impact the company's ability to continue providing AlloSure donor-derived cell-free DNA. While CareDx respectfully disagrees with the Supreme Court's decision, the case law applies equally to other transplant diagnostics patents, including Natera's (NTRA), and CareDx has filed a motion to invalidate Natera's patents on these same grounds.

17:39 EDT General Dynamics awarded $967.19M Navy contract modification - General Dynamics was awarded a $967.19M cost-plus-fixed-fee modification to a previously awarded contract for lead yard support and development studies and design efforts related to Virginia Class submarines. Work is expected to be completed by October 2024. FY23 research, development, test and evaluation funding in the amount of $110M and FY21 shipbuilding and conversion funding in the amount of $1M, will be obligated at time of award and will not expire at the end of the current fiscal year. Naval Sea Systems Command is the contracting activity.

17:14 EDT Teledyne to acquire Xena Networks, terms not disclosed - Teledyne Technologies announced that it has entered into an agreement to acquire Xena Networks ApS. Xena Networks, headquartered outside of Copenhagen, Denmark, is a provider of high-speed Terabit Ethernet validation, quality assurance, and production test solutions.

17:01 EDT Magic Empire Global declares special interim dividend of 1c per share - Magic Empire Global has declared a special interim dividend of 1c per ordinary share. The payout is the company's way of rewarding its shareholders for their support over the years. The dividend will be paid out on November 22 to the shareholders whose names are on the record at the close of business on October 16. The ex-dividend date is October 13.

16:45 EDT Natera says Supreme Court denies CareDx request for appeal in patent case - Natera (NTRA) announced that the United States Supreme Court denied CareDx's (CDNA) petition for certiorari concerning a patent infringement lawsuit brought by CareDx against Natera. This decision confirms the invalidity of the patents asserted against Natera and follows three previous rulings on the matter: a September 2021 decision by the United States District Court for the District of Delaware, affirming that all three CareDx patents asserted against Natera were invalid for claiming patent-ineligible subject matter; a June 2022 decision by the United States Court of Appeals for the Federal Circuit, affirming the Delaware Court's decision; a December 2022 denial of rehearing by the United States Court of Appeals for the Federal Circuit. This final decision by the Supreme Court rejects the request by CareDx to litigate this matter once again and effectively terminates any existing claims brought by CareDx against Natera concerning these patents.

16:33 EDT Airbnb director sells $23.0M in common stock - In a regulatory filing, Airbnb disclosed that its director Joseph Gebbia sold 166.7K shares of common stock on September 29th in a total transaction size of $23.0M.

16:31 EDT Athersys signs licensing agreement with Ardent Animal Health - The company states: "Athersys, announces the signing of a licensing agreement with Ardent Animal Health. Ardent is a privately held veterinary biotechnology company developing regenerative medicine and cancer therapies for animals. Under the terms of the agreement, Athersys will receive an initial fee from Ardent in exchange for an exclusive license to Athersys' Multipotent Adult Progenitor Cell technology for non-human mammal applications in the United States. The agreement includes pre- and post-regulatory approval milestone payments to Athersys, including payments on conditional and full product approval for each species/indication combination. Athersys will also receive tiered, double-digit royalties on commercial sales. Athersys has also granted Ardent rights of first refusal to be the exclusive distributor for Athersys' novel cryogenic storage system, the Secure Integrated Freezer Unit in the United States animal health space."

16:30 EDT Spotify to offer over 150,000 audiobooks as part of Spotify Premium subscription - Spotify announced: "Today we're starting an entirely new chapter for our audiobooks offering by making more than 150,000 audiobooks available as part of Spotify Premium subscriptions. To start, we're offering each Premium individual, as well as plan managers for Family and Duo accounts, 15 hours of listening per month-giving them the ability to enjoy as many titles as they want within that monthly allocation. What's more, this means eligible users are now getting even more from their Premium subscriptions: an on-demand catalog of more than 100 million tracks, 5 million podcasts, and over 150,000 audiobooks. This feature will be available for Premium users in the U.K. and Australia starting tomorrow, with the U.S. following later this year." Reference Link

16:24 EDT Phaxiam Therapeutics, Vetophage enter research partnership - Phaxiam Therapeutics and Vetophage announced the signature of a long-term strategic research partnership to combine their expertise in the research of new phages and phage-derived proteins in the fight against antimicrobial resistance. Vetophage is a Lyon-based biotechnology company founded in 2017. It develops new tools to detect pathogenic bacteria and alternative solutions to antibiotics based on phages and endolysins to tackle antimicrobial resistance in animals. Vetophage benefits from a wide range of capabilities for the discovery, identification and characterization of phages and endolysins. The company enables Phaxiam Therapeutics to screen its broad phage and endolysin bank targeting highly antimicrobial-resistant infections. This agreement gives Phaxiam Therapeutics exclusive licensing options on specified phages and endolysins in human health from the Vetophage platform, to further strengthen its product portfolio.

16:20 EDT Kezar Life Sciences to resume trading at 4:40 pm ET - Kezar Life Sciences is scheduled to resume trading at 4:40 pm ET, with quotation set to resume at 4:35 pm ET, according to Nasdaq. Shares were halted, pending news, ahead of the company announcing a strategic restructuring, 41% workforce reduction, and CEO change.

16:17 EDT Mind Technology Seamap unit received positioning systems orders for $3.4M - MIND Technology announced that its Seamap unit has received orders totaling approximately $3.4M for BuoyLink GNSS positioning systems. The majority of these orders are expected to be delivered in the next fiscal year.

16:16 EDT Larimar Therapeutics appoints Horizon Therapeutics CMO Jeffrey Sherman to board - Larimar Therapeutics (LRMR) announced the appointment of Jeffrey Sherman to the company's board of directors, effective immediately. Sherman, currently executive VP, chief medical officer, or CMO, at Horizon Therapeutics (HZNP), has over 20 years of executive experience in regulatory and clinical strategy.

16:13 EDT Globus Maritime regains compliance with Nasdaq - Globus Maritime announced that it has received a letter from Nasdaq, indicating that the company has regained compliance with the $1.00 per share minimum closing bid price requirement for continued listing on Nasdaq, pursuant to the Nasdaq marketplace rules. For at least 10 consecutive business days from September 18 to September 29, the closing bid price has been greater than $1.00. Nasdaq indicated within its letter that since the company has regained compliance with Listing Rule 5550, this matter is now closed.

16:12 EDT Kezar Life Sciences CEO John Fowler to step down - The company states: "John Fowler will be resigning from his role as Chief Executive Officer effective November 7, 2023, and Christopher Kirk, Ph.D. has been appointed as Chief Executive Officer. Dr. Kirk is a co-founder and member of the Board of Directors and previously served as Kezar's President and Chief Scientific Officer from March 2015 to April 2023. Mr. Fowler will continue as a member of Kezar's Board of Directors. In addition, Noreen Roth Henig, M.D., will be stepping down as Chief Medical Officer effective October 6, 2023. Zung To, SVP, Clinical Development Operations, will assume responsibilities for clinical trial execution and will oversee development operations."

16:11 EDT Kezar Life Sciences announces strategic restructuring, 41% workforce reduction - The company states: "Kezar Life Sciences announced it has initiated a strategic restructuring program to prioritize long-term growth and focus its resources on its clinical-stage programs. The strategic realignment is expected to extend operating capital to fund PALIZADE, Kezar's Phase 2b clinical trial in lupus nephritis. Actions to prioritize clinical programs and implement cost saving measures are expected to extend Kezar's cash runway into late 2026. These measures will focus resources to achieve important clinical data readouts for zetomipzomib in lupus nephritis and autoimmune hepatitis and KZR-261 in solid tumors. All research and drug discovery activities have been paused, and Kezar will explore strategic partnering alternatives for its protein secretion platform and preclinical programs. Kezar anticipates initial data from its KZR-261 Phase 1 clinical trial in 2024, topline data from its PORTOLA Phase 2a clinical trial in autoimmune hepatitis (AIH) in mid-2025 and topline data from PALIZADE in mid-2026. Kezar will reduce its workforce by approximately 41% to optimize capital allocation and align with strategic priorities. Kezar is also evaluating its Phase 1 clinical trial of KZR-261 in solid tumors and expects to reduce the number of planned expansion cohorts to conserve cash resources while it continues to evaluate safety and biologic activity in the ongoing trial."

16:10 EDT IGM Biosciences Michael Loberg, retires from board, Elizabeth Thompson appointed - IGM Biosciences announced that Michael Loberg, Ph.D. has retired from its Board of Directors, including as Chairman, effective October 3 . Loberg has served as a member of the IGM Biosciences Board of Directors since 2015 and as Chairman of the Board since 2018. IGM Biosciences is also pleased to announce the appointment of Elizabeth H.Z. Thompson, Ph.D. to its Board of Directors. Dr. Thompson is an accomplished drug development professional who has been involved in the development of important marketed medicines, most recently as the Executive Vice President of Research and Development at Horizon Therapeutics.

16:10 EDT MKUL Stock trading resumes

16:09 EDT Cal-Maine Foods CEO says facing ongoing challenges with HPAI threat, inflation - "We look forward to the opportunities ahead for Cal-Maine Foods in fiscal 2024. While we face ongoing challenges related to the threat of HPAI and inflationary headwinds, we will continue to manage the aspects of our business we can control. We are uniquely positioned to support the nation's food supply with nutritious and affordable protein, and we believe demand for our products will continue to grow. We are confident we have the right strategy in place to meet this demand, with a proven operating model that will drive long-term growth. Across our operations, we have a shared commitment to our mission to be the most reliable and sustainable producer of fresh shell eggs and egg products. Importantly, we have a dedicated workforce, and sufficient capital to fund internal expansion projects and consider additional potential acquisitions to support our strategy. Above all, we will strive to meet the demands of our valued customers and deliver greater value to our shareholders."

16:07 EDT Accuray announces approval for Tomo C radiation therapy system in China - Accuray announced that the registration dossier for the CNNC-Accuray joint venture Tomo C radiation therapy system for the Type B market has been approved by the Chinese National Medical Products Administration, or NMPA. The new, made in China system, is the first joint venture product and represents an important achievement on behalf of cancer patients, many of whom will need treatment with radiotherapy at least once to cure their cancer, increase the chance of cure or relieve symptoms caused by cancer. The Tomo C platform features helical imaging and radiation delivery. With fully-integrated treatment planning, centralized data management and ultra-precise treatment delivery using patented beam-shaping technology, the system enables greater control of the radiation dose so it conforms precisely to the tumor and helps minimize dose to healthy tissue.

16:06 EDT Intel to separate PSG operations into standalone business - Intel Corporation announced its intent to separate its Programmable Solutions Group operations into a standalone business. This will give PSG the autonomy and flexibility it needs to fully accelerate its growth and more effectively compete in the FPGA industry, which serves a broad array of markets, including the data center, communications, industrial, automotive, aerospace and defense sectors. Intel also announced that Sandra Rivera, executive vice president at Intel, will assume leadership of PSG as chief executive officer; Shannon Poulin has been named chief operating officer. Standalone operations for PSG are expected to begin Jan. 1, 2024, with ongoing support from Intel. Intel expects to report PSG as a separate business unit when it releases first-quarter 2024 financials. Over the next two to three years, Intel intends to conduct an IPO for PSG and may explore opportunities with private investors to accelerate the business's growth, with Intel retaining a majority stake. The two companies will remain strategically aligned, including continuing PSG's relationship with Intel Foundry Services, as they work together to address key areas of the FPGA market. Building on PSG's highly successful Supply Resilience program pilot, the relationship with IFS will also uniquely enable PSG to give customers greater predictability of supply aligned to their needs, ensuring a more resilient supply chain. "Our intention to establish PSG as a standalone business and pursue an IPO is another example of how we are consistently unlocking more value for our stakeholders. This will give PSG the independence it needs to keep growing share in the FPGA market, differentiating itself with capacity and supply resilience from IFS, and allowing Intel product teams to focus on our core business and long-term strategy," said Intel CEO Pat Gelsinger. "Sandra has proven herself by reinvigorating DCAI, placing it on a path for success. I am confident she will bring PSG that same dedication, energy and customer commitment."

16:05 EDT United Airlines orders 50 more Boeing 787 Dreamliners - Boeing (BA) and United Airlines (UAL) announced the carrier is expanding its 787 Dreamliner fleet, exercising options to order 50 787-9 airplanes and securing an additional 50 options. The new Dreamliner order provides United additional flexibility as the airline modernizes its global fleet over the next decade. With 150 firm orders, United has the largest Dreamliner orderbook on record and is positioned to become the largest 787 operator in the world.

16:04 EDT Ocular Therapeutix initiates first OTX-TKI trial - Ocular Therapeutix announced the initiation of its first pivotal clinical trial to evaluate OTX-TKI, the company's axitinib intravitreal implant, for the treatment of wet age-related macular degeneration, or wet AMD. OTX-TKI is also being developed for the treatment of diabetic retinopathy and other retinal diseases.

15:51 EDT Novavax 2023-2024 COVID vaccine now authorized, recommended for use in U.S. - Novavax announced that the Novavax COVID-19 Vaccine, Adjuvanted has received Emergency Use Authorization from the U.S. Food and Drug Administration for active immunization to prevent COVID-19 in individuals aged 12 and older. Immediately upon authorization, Novavax's vaccine has also been included in the recommendations issued by the U.S. Centers for Disease Control and Prevention on September 12, 2023. Doses will be available nationwide at thousands of locations, including national and local retail pharmacies and physicians' offices, following the Center for Biologics Evaluation and Research release of vaccine batches, expected in the coming days. "COVID-19 is once again on the rise with infections and hospitalizations increasing, so it's important that individuals get vaccinated to protect themselves and their loved ones," said John C. Jacobs, President and Chief Executive Officer, Novavax. "Novavax's authorization today means people will now have the choice of a protein-based non-MRNA option to help protect themselves against COVID-19, which is now the fourth leading cause of death in the U.S. In the coming days, individuals in the U.S. can go to pharmacies, physicians' offices, clinics and various government entities to receive an updated Novavax vaccine."

15:36 EDT Molson Coors sees high-single-digit annual underlying EPS growth over long-term - Molson Coors Beverage introduced a new plan to accelerate its growth, its long-term financial outlook, and new capital deployment plans. The Acceleration Plan, designed to build upon the company's growth in the years ahead, was shared at the company's 2023 Strategy Day, the company announced. The long-term financial outlook includes: Low-single-digit annual net sales revenue growth, on a constant currency basis; Mid-single-digit annual underlying income before income taxes growth, on a constant currency basis; High-single-digit annual underlying earnings per share growth; and net debt to underlying EBITDA of under 2.5x over the long term. "Our long-term growth algorithm anticipates net sales revenue growth, margin expansion, and attractive earnings per share growth, while our expected compelling free cash flow generation supports reinvestment in value creation. With substantially improved financial flexibility, we are pleased to announce a new $2 billion share repurchase program as part of our balanced and cohesive approach of prioritizing capital allocation among investing in our business, reducing net debt, and returning cash to shareholders. As we look to the future, we are confident in our strategy and ability to drive compelling returns for our shareholders," said CFO Tracey Joubert.

15:31 EDT Home Plate Acquisition cancels special holder meeting, announces liquidation - Home Plate Acquisition Corporation announced that the company has cancelled its special meeting of stockholders that was previously scheduled for 3:00 p.m. Eastern Time on October 3, 2023, and that, because the company will not consummate an initial business combination by October 4, 2023, the time period required by the company's Amended and Restated Certificate of Incorporation to consummate a business combination, promptly as reasonably possible after October 4, 2023, the company intends to dissolve and liquidate in accordance with the provisions of its Amended and Restated Certificate of Incorporation and will redeem all of the outstanding shares of Class A common stock that were included in the units issued in its initial public offering, at what the company estimates will be a per-share redemption price of approximately $10.52. The company has been informed by Heidmar Inc. that Heidmar intends to terminate the Business Combination Agreement previously entered into between Home Plate and Heidmar promptly on or following October 4, 2023, the time period required by the company's Amended and Restated Certificate of Incorporation to consummate a business combination. As of the close of business on October 4, 2023, the Public Shares will be deemed cancelled and will represent only the right to receive the redemption amount. Record holders as of the close of business on October 3, 2023 will receive their pro rata portion of the proceeds of the trust account less dissolution expenses and net of taxes payable by delivering their Public Shares to Continental Stock Transfer & Trust Company, the company's transfer agent. Beneficial owners of Public Shares held in "street name," however, will not need to take any action in order to receive the redemption amount. The redemption of the Public Shares is expected to be completed within ten business days after October 4, 2023. The Company's sponsor has agreed to waive its redemption rights with respect to its outstanding Class A common stock issued prior to the company's initial public offering. There will be no redemption rights or liquidating distributions with respect to the Company's warrants, which will expire worthless. The company expects that NASDAQ will file a Form 25 with the United States Securities and Exchange Commission to delist the company's securities. The company thereafter expects to file a Form 15 with the Commission to terminate the registration of its securities under the Securities Exchange Act of 1934, as amended.

15:28 EDT Molson Coors announces new $2B share repurchase program - Program to be executed over next five years. Share buyback program announced during ongoing strategy day meeting.

15:17 EDT Zoom says new AI Companion capabilties available at no additional cost - Zoom Video said that all the new AI Companion capabilities announced at its Zoomtopia event are available at no additional cost with the paid services assigned to one's Zoom user account. The company said that AI Companion is a generative AI assistant on the Zoom platform, with new capabilities including meeting summary notes, the ability to generate entire email messages based on a simple prompt, more Zoom Whiteboard features, and smart recordings for meetings. Reference Link

15:00 EDT MKUL Stock trading halted, news pending

14:35 EDT U.S. FCC issues $150K first ever fine for space debris to Dish Network - The FCC's Enforcement Bureau announced a settlement of its investigation into DISH for failure to properly deorbit its EchoStar-7 satellite. This marks a first in space debris enforcement by the Commission, which has stepped up its satellite policy efforts, including establishing the Space Bureau and implementing its Space Innovation Agenda. The settlement includes an admission of liability from the company and an agreement to adhere to a compliance plan and pay a penalty of $150,000. The FCC's investigation found that the company violated the Communications Act, the FCC rules, and the terms of the company's license by relocating its direct broadcast satellite or DBS, service EchoStar-7 satellite at the satellite's end-of-mission to a disposal orbit well below the elevation required by the terms of its license. At this lower altitude, it could pose orbital debris concerns. "As satellite operations become more prevalent and the space economy accelerates, we must be certain that operators comply with their commitments," said Enforcement Bureau Chief Loyaan A. Egal. "This is a breakthrough settlement, making very clear the FCC has strong enforcement authority and capability to enforce its vitally important space debris rules."

14:30 EDT Nissan reports Q3 U.S. sales up 40.8% to 216,878 units - Nissan Group announced total U.S. third-quarter July - September sales for 2023 of 216,878 units, an increase of 40.8% versus the prior year. Reference Link

14:00 EDT Molson Coors sees high-single digit growth in underlying EPS over long-term - Molson Coors shared a long-term annual growth algorithm that includes net sales revenue in constant currency growing by a low-single digit percentage and underlying earnings per share growing by a high-single digit percentage. The long-term growth algorithm is being discussed during the company's ongoing strategy day meeting. Shares remain halted for news pending. Reference Link

13:24 EDT Molson Coors trading halted, news pending

13:13 EDT Green Dot, Stockpile partner to deliver financial services to investors - Green Dot Corporation and Stockpile announced a new partnership to introduce products, tools and features "aimed at making investing and personal finance more accessible to consumers of all ages." Powered by Green Dot's banking-as-a-service platform, the companies said Stockpile will embed parental spending controls and debit card functionality for minors in its retail investing product suite, with additional features and functionality planned for the future. "Green Dot's depth of experience embedding seamless, innovative and value-driven financial tools into their partner ecosystems, along with their passion for providing accessible financial services to consumers and businesses, make them a great fit for Stockpile's long-term vision and growth trajectory," said Victor Wang, CEO, Stockpile, Inc. "Partnering with Green Dot adds a new dimension to Stockpile's hands-on financial learning and access, and will deliver a seamless and responsible debit card experience as an educational stepping stone to investing."

13:07 EDT Capybara Research says FingerMotion relies on accounting gimmicks, sets $1 target - In a recently published report, Capybara Research says it holds a short position in shares of FingerMotion (FNGR) and that it believes the stock price is headed lower, as the promotional campaign ends and share dilution begins. "The company's $300 million Shelf Registration and $25 million ATM agreement are likely triggers for significant shareholder dilution. We believe FingerMotion relies on accounting gimmicks to portray large revenue growth. FingerMotion's balance sheet is deteriorating with eroding gross margins, and concurrently, its cash burn is on the rise. This combination paints a concerning picture of the company's financial health," the report reads. Furthermore, Capybara Research says "it is evident that FingerMotion is operating with a fundamentally flawed business model that deviates from the path to profitability... Inevitably, the company will resort to diluting its stock through the execution of its shelf registration, whether through its ATM agreement, secondary offerings, or large amounts of shares held by insiders with negative intentions to shareholders. Ultimately, the losers in this situation will be the unsuspecting investors who become ensnared in this investment trap. As a result, we iterate a $1 price target." Reference Link

12:36 EDT Google introduces new requirements for Gmail bulk senders - Alphabet's Google introduced new requirements for bulk senders - those who send more than 5,000 messages to Gmail addresses in one day - to keep users' Gmail inboxes even safer and more spam-free. By February 2024, Gmail will start to require that bulk senders authenticate their email, enable easy unsubscription, and ensure they're sending wanted email. "These practices should be considered basic email hygiene, and many senders already meet most of these requirements," the company said. "For those who need help to improve their systems, we're sharing clear guidance before enforcement begins in February 2024. These changes are like a tune-up for the email world, and by fixing a few things under the hood, we can keep email running smoothly. But just like a tune-up, this is not a one-time exercise. Keeping email more secure, user friendly and spam-free requires constant collaboration and vigilance from the entire email community. And we'll keep working together to make sure your inbox stays safe." Reference Link

12:29 EDT Mitsubishi Motors North America reports Q3 sales up 32.3% y/y to 22,196 units - Mitsubishi Motors North America reported 22,196 sales for the third quarter of 2023, an increase of 32.3% over the same period the year before. On a year-to-date basis, sales of 67,736 represent an increase of 4.1%.

12:14 EDT Honda reports September U.S. sales up 45.5% to 115,437 units - American Honda said total sales topped 115,000 units, up 45.5%, in September and 52.7% in Q3, "despite supply constraints for some models." CR-V and Accord hybrid-electric models combined for 218,684 in the first nine months of 2023 and already set annual electrified records, the company said in a statement.

12:04 EDT General Motors reports Q3 U.S. sales 674,336 vehicles, up 21% y/y - General Motors and its dealers delivered 674,336 vehicles in the U.S. in the third quarter of 2023, up 21% year-over-year. Strong customer demand for GM's portfolio of trucks and SUVs drove sales growth across all its brands in the third quarter, GM said. GM's total sales are up 19% for the calendar year, the company said in a statement.

12:00 EDT Brandywine Realty falls -10.7% - Brandywine Realty is down -10.7%, or -47c to $3.92.

12:00 EDT Enhabit falls -21.7% - Enhabit is down -21.7%, or -$2.55 to $9.18.

12:00 EDT Lifezone Metals rises 8.2% - Lifezone Metals is up 8.2%, or 92c to $12.11.

11:57 EDT Inhibikase Therapeutics treatment of Multiple System Atrophy gets orphan status - Inhibikase Therapeutics' treatment of Multiple System Atrophy was granted FDA orphan designation, according to a post to the agency's website. Reference Link

11:31 EDT Toyota Motor North America reports U.S. September sales of 203,904 vehicles - Toyota Motor North America reported U.S. September 2023 sales of 203,904 vehicles, up 13.9% on a volume basis and up 9.5% on a daily selling rate basis versus September 2022. September 2023 sales of electrified vehicles totaled 64,298, representing 31.5% of total monthly sales. For the third quarter of 2023, TMNA reported U.S. sales of 590,296 vehicles, up 12.2% on a volume basis and up 10.8% on a DSR basis. Third quarter electrified vehicle sales totaled 184,666, representing 31.3% of total year-to-date sales. "With the introduction of several electrified vehicles including the all-new Toyota Grand Highlander hybrid, Toyota Corolla Cross hybrid, Toyota Prius, and the Lexus RX plug-in hybrid, customers now have 26 Toyota and Lexus electrified vehicle options to choose from, the most among any automaker," said Jack Hollis, executive vice president, Sales, TMNA. "We anticipate continued strong sales momentum as we close out 2023 as dealer stock improves and key new products like the fourth generation Toyota Tacoma and Lexus TX and TX hybrid hit showroom floors."

11:18 EDT Subaru of America reports September sales up 23.4% to 56,335 vehicles - Subaru of America reported 56,335 vehicles sold for September, a 23.4% increase compared with a September 2022 total of 45,658. SOA also reported year-to-date sales of 467,223, a 16.5% increase compared with the same period in 2022.

11:07 EDT Golden Ocean to extend existing share buy-back program further 12 months - The board of directors of Golden Ocean Group Limited has on October 3 resolved to extend the existing share buy-back program with a further 12 months. The main terms remain unchanged: Maximum $100M to purchase up to an aggregate of 10M of the company's common shares, with 1,507,328 shares repurchased $11,629,758 as of the date hereof; A period up to 12 months from and including October 5, 2023; the share buy-backs will be carried out by way of repurchases in the market, both on the Oslo Stock Exchange and on NASDAQ. The company will execute and report buy-backs carried out continuously and in accordance with the disclosure requirements of the Oslo Stock Exchange. Lars-Christian Svensen, Interim CEO, comments: "The volatility in capital markets and dry bulk freight sentiment continues, and our share is trading at a discount to underlying substance values. We believe it is in the shareholders' interest to extend the authorization to repurchase our common stock as part of its capital allocation strategy. During the past 12 months, we have repurchased 1.5 million shares at attractive levels and will opportunistically utilize the extended program as a supplement to our long-term focus on dividend."

11:02 EDT Mattel, Gamefam announce launch of 'Barbie Dreamhouse Tycoon' on Roblox - Mattel and Gamefam announced the upcoming launch of Barbie DreamHouse Tycoon on Roblox on October 6. After recording three million unique visits in beta, the first-ever official Barbie Roblox game is jam-packed with endless imagination and features everything fans could ask for, including the chance to build their very own DreamHouse, live out various careers, and unleash their inner fashion icon.

10:46 EDT U.S. Air Force awards RTX $39M for air defense command, control prototype - The U.S. Air Force awarded Raytheon $39M to develop and integrate the service's Battle Management Command and Control software into a prototype for air base air defense. Under this contract, Raytheon will develop the command-and-control foundation to counter airborne threats and defend U.S. air bases around the world.

10:15 EDT Sonder Holdings trading resumes

10:10 EDT WeTrade: Report purporting change of offers was submitted without authorization - WeTrade Group announced that the September 28, 2023 current report on Form 8-K filed with the SEC, purporting a change of the company's directors and officers, was submitted to EDGAR without proper authorization of the company. There were no changes to the Board of Directors and investors should not rely on the disclosures contained therein. The Board of Directors and officers are still remained the same as follow: Guo Bi Ming (Chairman), Wei He Chun (CEO), Annie Huang (CFO), Grace Li (Director), Qin Ning (Director), Ye Yu Xing (Director) and Li Da Xue (Director). On September 28, 2023, a derivative lawsuit was filed in the United States District Court District of Wyoming against certain officers and directors of the company by certain shareholders. The complaint alleges that the Named Defendants were no longer officers and directors of the company as of June 30, 2023 and that the corporate actions relating to certain share issuances to private placement investors were unauthorized. A motion for temporary restraining order and preliminary injunction was filed on September 28, 2023 to temporarily restrain the Named Defendants from acting on behalf of the company. The company believes that the complaint is meritless and will vigorously defend it.

10:00 EDT Carriage Services falls -9.6% - Carriage Services is down -9.6%, or -$2.67 to $25.16.

10:00 EDT Enhabit falls -15.0% - Enhabit is down -15.0%, or -$1.77 to $9.96.

10:00 EDT Fast II rises 10.2% - Fast II is up 10.2%, or $1.25 to $13.50.

09:47 EDT Sibanye Stillwater falls -6.7% - Sibanye Stillwater is down -6.7%, or -39c to $5.46.

09:47 EDT Enhabit falls -9.1% - Enhabit is down -9.1%, or -$1.07 to $10.66.

09:47 EDT Warby Parker rises 8.1% - Warby Parker is up 8.1%, or $1.07 to $14.34.

09:37 EDT Knightscope announces three new sales for K1B Emergency Communications Systems - Knightscope announces three new sales for its K1B Emergency Communications Systems. The three orders were placed by a college in Pennsylvania and two hospital systems - one in Illinois and one in Indiana.

09:36 EDT FDA staff voice concerns about whether Amgen's CodeBreaK 200 trial 'adequate' - Background information prepared by the Food and Drug Administration staff for the panel members of the Oncologic Drugs Advisory Committee Meeting being called on October 5 to review the sotorasib new drug application made by Amgen states in part: "CodeBreaK 200 was a trial designed to verify the clinical benefit of single agent sotorasib vs docetaxel, after the initial accelerated approval of sotorasib based on single arm data yielding an ORR of 36%. However, the trial results are confounded by multiple sources of systemic bias, raising concerns about whether CodeBreaK 200 can be considered an adequate and wellcontrolled trial. Furthermore, the primary endpoint of PFS by BICR may not be reliable, given its magnitude relative to the imaging interval." Reference Link

09:27 EDT Applied Digital up 3% in pre-market after being started at Buy at Roth MKM - Shares of Applied Digital are up 3% in pre-market trading at $6.31. The stock was initiated with a Buy rating at Roth MKM last night, with the firm calling the company an "agnostic provider for the AI arms race".

09:24 EDT Agree Realty CEO buys $215.4K in common stock - In a regulatory filing, Agree Realty disclosed that its CEO Joey Agree bought 4K shares of common stock on October 2nd in a total transaction size of $215.4K.

09:23 EDT FMW Media signs a 12-part series for interviews, commercials about Surf Air - FMW Media's business TV show, New to The Street, announces the signing of a 12-part series for filming and broadcasting tailored interviews and commercials about Surf Air Mobility. During the week of October 1, 2023, New to The Street's TV Host Jane King is filming at the New York Stock Exchange Studio, interviewing SRFM's management about the Company's regional airline business and its development and commercialization of electrified aircraft for green regional air mobility. New to The Street will air all SRFM's interviews on three major cable televised outlets, Newsmax, the FOX Business Network, and Bloomberg TV, as a sponsoring program. Jamie Strecker, Surf Air Mobility's Head of Business Development states, "We aim to transform regional flying through the power of electrification. Sharing our unique story through New to the Street will help us reach and enlighten key audiences about the exciting future and benefits that electrified air travel will bring to consumers and businesses."

09:22 EDT Neuronetics draws down remaining $22.5M under credit facility - Neuronetics has drawn down the remaining $22.5 million from its credit facility with SLR Capital Partners. "We are pleased to have successfully drawn down the remaining capital as part of our credit facility with SLR, which further bolsters our balance sheet in a non-dilutive manner and will support the ongoing execution of our strategy," said Keith Sullivan, CEO. "Given the current challenging equity and debt capital markets environment, we felt it was prudent to strengthen our balance sheet in a cost-effective manner. The Company continues to believe that it can attain self-sustainability with the previous cash balance and that it can achieve cash flow break-even in Q4-2024 and on a full-year basis in 2025. This incremental capital should remove any doubt about the Company needing to access the equity markets. I want to thank SLR for their continued support of our vision to advance neurohealth therapies and drive the further adoption of NeuroStar Advanced Therapy for mental health."

09:17 EDT Gogo: Skyservice Business Aviation gets STC approval for Gogo 5G system - Skyservice Business Aviation, in partnership with Gogo Business Aviation, has received Supplemental Type Certification approval from Transport Canada for the Gogo 5G system on Bombardier (BDRBF) Challenger 300 series aircraft. Skyservice, a Gogo authorized dealer in Canada, completed the certification on Sept. 1. The comprehensive Transport Canada Civil Aviation (TCCA) STC, followed by Federal Aviation Administration validation, is available for Challenger 300 operators who install a Gogo AVANCE L5 today along with the full Gogo 5G provisional kit.

09:13 EDT CleanSpark reports FY23 bitcoin production up 84% year-over-year - CleanSpark released its unaudited bitcoin mining and operations update for September 30. The company mined 6,903 bitcoin during its fiscal year ending September 30, 2023. Construction is proceeding according to schedule for the expansion of CleanSpark's Sandersville, GA, bitcoin mining data center. Bitcoin mined in September: 643. Total BTC holdings as of September 30: 2,240. Current hashrate: 9.6 EH/s. The company sold 80 bitcoin in September at an average of approximately $26,800 per BTC. Sales of BTC equated to proceeds of approximately $2.2M. In Sandersville, no serious delays have been reported and site construction remains on track for yearend completion.

09:09 EDT WideOpenWest to build all fiber network in Hernando County, Florida - WideOpenWest's WOW! Internet, TV & Phone plans to expand its footprint in communities along Florida's west central coast. Construction will begin in the coming months to bring WOW!'s all-IP fiber network to Hernando County. The company plans to add 44,000 new homes to its subscriber base, bringing the total number of identified homes in its Greenfield expansion efforts to 389,000. WOW! has already made progress in its previously identified Greenfield markets, including Orange and Seminole counties in Central Florida, where services are launching across multiple communities, and Greenville County, South Carolina, where construction is underway and services are nearing launch.

09:08 EDT AGBA Acquisition submits letter to SEC, Nasdaq on irregular trading activities - AGBA Group Holding provides updates on its actions against certain irregular trading activities in the Company's ordinary shares. On October 3, 2023, AGBA submitted a letter to the Securities and Exchange Commission and to Nasdaq regarding irregular trading activities in the Company's ordinary shares by unknown parties since April 28, 2023. On those irregular trading days, trading volume represented more than 100% of the Company's freely tradeable shares. AGBA is taking these matters seriously and is committed to ensuring that the Company's shareholders are protected.

09:07 EDT LPL Financial announces Joe Bryant, Jamie Bryant join Linsco - LPL Financial announced that father and daughter financial advisors Joe Bryant and Jamie Bryant have joined LPL's employee advisor channel, Linsco by LPL Financial, to launch Winner's Circle Wealth Management of LPL Financial. They reported having served approximately $125 million in advisory, brokerage and retirement plan assets and join LPL from Robert W. Baird & Co.

09:06 EDT Kyndryl Holdings and Palo Alto Networks partner in cybersecurities services - Kyndryl (KD) announced a strategic global alliance with Palo Alto Networks (PANW) to provide end-to-end network and cybersecurity services, including the launch of a new service offering, powered by Prisma SD-WAN for enterprises and Industry 4.0 customers. The alliance brings together Palo Alto Networks' platform security capabilities with Kyndryl's network security services expertise to design, build, manage, and modernize mission-critical networking for customers across industries. The companies are joining forces to capitalize on emerging opportunities in the SD-WAN infrastructure market that IDC estimates will grow at a compound annual growth rate of 10.1% through 2027. The global partnership between Kyndryl and Palo Alto Networks builds on the companies' collaboration around security services and solutions. In July Kyndryl launched its new Security Operations as a platform solution leveraging Palo Alto Networks Cortex technology to drive operational savings and time-to-value through automation and orchestration.

09:06 EDT Scilex provides notice to record holders, beneficial owners of restricted shares - Scilex Holding Company provides notice to all record holders and beneficial owners of restricted shares of Scilex common stock that were part of the previously announced dividend of Scilex common stock then-held by Sorrento Therapeutics, Inc. to Sorrento equity holders of record as of January 9, 2023. On December 30, 2022, Sorrento Therapeutics announced that its board of directors authorized Sorrento to dividend to Sorrento equity holders of record as of January 9, 2023 an aggregate of 76,000,000 shares of common stock of Scilex Holding Company that were then-held by Sorrento. The Scilex Dividend Stock was distributed on or about January 19, 2023 and since such date has been subject to restrictions on transfer which are currently in place through March 31, 2024. The Scilex Dividend Stock was primarily received by "record holders," or brokers, dealers, banks and other nominees acting as agents for shareholders who are the true "beneficial owners" of the Scilex Dividend Stock. On February 13, 2023, Sorrento and certain of its related entities which did not include Scilex, commenced voluntary proceedings under Chapter 11 of the United States Code in the United States Bankruptcy Court for the Southern District of Texas. The Chapter 11 proceedings are jointly administered under the caption In re Sorrento Therapeutics, Inc., et al. According to Sorrento's estimates, approximately 8.4 million or more shares of Scilex common stock were deemed to have been sold "short" as of the Payment Date as a result of the "short" positions of the underlying Sorrento common stock. "Naked short" sales or "naked short" positions in any Scilex common stock may constitute a violation of SEC Regulation SHO. On June 12, 2023, the Official Committee of Equity Securities Holders of the Debtors commenced an adversary proceeding in the Bankruptcy Proceedings by filing a complaint against certain brokerage firms seeking entry of a temporary restraining order and preliminary injunction related to the defendants' allowance and facilitation of illegal naked short selling of Scilex common stock. On June 14, 2023, the Bankruptcy Court entered a temporary restraining order temporarily suspending all short sales of Scilex Dividend Stock and ordering the defendants to provide an accounting of all profits received from the naked short selling of Scilex Dividend Stock and Scilex common stock, including all interest charged to short sellers, no later than five business days after entry of the order. On July 18, 2023, the Bankruptcy Court then granted the joint emergency motion filed by the Debtors and the Equity Committee for an order approving and authorizing the Debtors to consummate an offering of shares of Scilex common stock held by the Debtors, authorizing entry into settlement agreements with participating record holders of Scilex common stock who opt into a settlement, and granting related relief. This emergency motion was very successful, resulting in settlements reached with dozens of short sellers and approximately 800,000 Scilex common stock short positions closed or covered.

09:05 EDT Baxter Sysco appoints Joel Grade CFO - Baxter International (BAX) announced it has appointed Joel Grade as executive vice president and chief financial officer CFO reporting to Baxter chairman, president and CEO, Jose E. Almeida, effective Oct. 18. At that time, Brian Stevens, who has served as the company's interim CFO since May 31, 2023, will transition to his prior role as senior vice president, chief accounting officer and controller. "Joel is a seasoned global financial executive with decades of deep operational and broad business experience as well as a proven record of results-driven impact," said Mr. Almeida. .. Grade, 53, joins following a distinguished 25-year career with Sysco (SYYY), the world's global foodservice leader with fiscal-year 2023 sales of more than $76B. Mr. Grade brings deep experience from various financial, commercial and executive leadership roles. He most recently served as Sysco's executive vice president, corporate development, and previously held the roles of executive vice president and CFO as well as senior vice president of finance and chief accounting officer, and senior vice president of foodservice operations.

09:03 EDT Medical Properties Trust receives Australian FIRB approval of facility sale - Medical Properties Trust announced that the Australian Foreign Investment Review Board, or FIRB, has approved HMC Capital's purchase of MPT's remaining four Australian facilities for approximately A$470M. The transaction is expected to close in October. The 5.7% cash cap rate on the sale demonstrates continued significant third-party demand for essential hospital real estate at pricing that validates MPT's underwriting, notwithstanding broader macroeconomic market conditions.

09:02 EDT CNH Industrial expands harvesting stake with investment in Advanced Farm - CNH continues to support the acceleration of smart harvesting technologies with a minority investment in the California-based start-up Advanced Farm Technologies, which specializes in the robotic harvesting of apples, strawberries and other fruits. The two businesses will partner to drive industry and ecosystem innovation by collaborating across R&D and commercialization.

09:01 EDT Galaxy Gaming to unveil new content at Global Gaming Expo - Galaxy Gaming will unveil innovative new content and technology at this year's Global Gaming Expo from October 10-12 in booth #4016. "We're thrilled to be exhibiting at G2E and for the opportunity meet with our customers and showcase some of the exhilarating new products and titles we've been working on," shared Todd Cravens, President and CEO of Galaxy Gaming. "Through our investment in building the best-in-class operating system, developing thrilling new and proven titles, and our strong iGaming roadmap, we remain committed to delivering the greatest table games experience to everyone, everywhere."

08:51 EDT Sadot releases latest Corporate Update report - Sadot Group announced the release of its latest Corporate Update. "Following our strategic pivot to the global food supply chain sector, we are pleased to announce in our latest Corporate Update significant milestones across each of our core verticals as we continue to execute on our plans initiated earlier this year. This focus has allowed us to fortify our financial position, allowing us redirect resources towards the growth of our agri-foods supply chain business, reinforcing our dedication to enhancing shareholder value," stated CEO Michael Roper.

08:51 EDT PNC Financial acquires $16.6B in Signature Bank capital commitments facilities - PNC Bank has acquired a portfolio of capital commitments facilities from Signature Bridge Bank, through an agreement with the Federal Deposit Insurance Corporation as Receiver. The transaction closed Oct. 2. The FDIC established Signature Bridge Bank on March 12, after being appointed receiver of the former Signature Bank, New York by the New York State Department of Financial Services. The acquired portfolio represents $16.6B in total commitments, including $9B of funded loans. The transaction, to be funded with cash on hand, is expected to be immediately accretive to PNC's earnings, and will represent approximately 10c per share in Q4. The transaction will not have a material impact to PNC's total assets, capital ratios or tangible book value per share.

08:50 EDT Camber Energy enters agreement with Planeteq - Camber Energy announced that Simson-Maxwell entered into a Manufacturer's Representative Agreement with Planeteq Limited pursuant to which Planeteq was appointed as the exclusive distributor of Viking Ozone Technology's proprietary ozone waste treatment systems in the United Kingdom.

08:48 EDT LightPath completes expansion, renovation of Orlando facility - LightPath Technologies announced the completion of the Company's expansion and renovation of their facility in Orlando. With over $5 million invested, the facility's total footprint grew from 34,000 square feet to 55,000 square feet. Within the expanded footprint, the Company was able to nearly triple its cleanroom space from 4,000 square feet to 11,700 square feet, increasing the Company's capacity to support the strategically important assemblies and camera sub-systems businesses. The two Orlando facilities were consolidated into one as part of the renovation, streamlining manufacturing processes. In addition, 6,500 square feet was added to dedicated engineering space, with most of that composing lab space. Additional room to expand glass manufacturing, including coating and assembly, was prepared for future use.

08:47 EDT BK Technologies receives purchase order for BKR 9000 - BK Technologies received a purchase order from the Sandoval County Office of Emergency Management valued at $963,0000, for its BKR 9000 multiband radio. The purchase was made through Advanced Communications and Electronics of Albuquerque, New Mexico, an authorized dealer of BK Technologies communications technology.

08:46 EDT Yield10 Bioscience completes harvest of majority 2023 winter, spring Camelina - Yield10 Bioscience announced that the harvest of a majority of the winter and spring Camelina sativa grain produced under grower contracts in 2022/2023 has been completed. This harvest marks the establishment of the Company's "Camelina Seed Genetics to Biofuel" platform, as the Camelina grain is being delivered to an offtake partner that has crushed the grain and refined the oil into biofuel. As a result, Yield10 has begun generating revenue from Camelina grain delivery for the production of feedstock oil for sustainable transportation fuels. "We are extremely pleased to achieve this milestone of generating revenue by commercializing our 'Camelina Seed Genetics to Biofuel' platform," said Oliver Peoples, Ph.D. President and Chief Executive Officer of Yield10 Bioscience. "This was achieved through the commitment and dedication of the Yield10 team working closely with growers as partners. As we have transitioned to the commercialization of Camelina, we can now turn our focus to building the technology foundation to accelerate grower adoption of Camelina for the biofuels market. We believe that our herbicide tolerant Camelina varieties, currently progressing through development, regulatory review and scale-up, will play a vital role in our strategy to grow acreage substantially over time. We remain focused on meeting our future commercialization goals and plan to continue revenue generation and ultimately to fully realize our vision for Yield10."

08:44 EDT Exscientia provided an update on its pipeline prioritisation strategy - Exscientia provided an update on its pipeline prioritisation strategy designed to further strengthen the Company's focus, investment and infrastructure on programmes of greatest potential for differentiation and value creation. Exscientia has built a highly efficient and versatile AI-led drug discovery platform. To date, its platform has yielded eight differentiated clinical development candidates across a variety of therapeutic areas, and at a pace that is substantially faster than current industry standards. The Company anticipates its capabilities will continue to grow, driven by recent investments in automation as well as other leading technological and scientific advancements which may further accelerate pipeline growth. In this context, the Company intends to prioritise its internal development efforts and focus its resources on the most differentiated, highest value oncology targets within its portfolio, such as LSD1 and CDK7. This strategic focus is designed to allow Exscientia to maximise its pipeline value and output while continuing to develop novel technologies to transform drug discovery and development. In addition, it will enhance operational and financial efficiency with a cash runway well into 2026. "Exscientia creates value by using technology to solve previously unsolved discovery challenges and achieving great data-driven operating efficiency," said Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive Officer of Exscientia.

08:43 EDT Foremost Lithium to complete LiDAR survey on Peg North property - Foremost Lithium Resource & Technology announced that EarthEx Geophysical Solutions Inc. will commence LiDAR surveying at the Company's Peg North property the week of October 9, 2023. The upcoming LiDAR survey on the Peg North claim block will complete the collection of LiDAR and high-resolution magnetics over the entirety of Foremost's "Lithium Lane" properties in the Snow Lake area, including its Jean Lake, Grass River, Zoro and Peg North properties. Foremost has flown a total of 7,472.7-line km of drone-borne magnetics, using the exMAG system over its entire 43,000+ acres/17,500 ha land package. The drone magnetometer surveys were flown with a flightline azimuth of 070degrees and flight-line spacing of 25m. Tie lines were established at 250m spacing. "Completing the LiDAR surveying over the entirety of our Lithium Lane properties is an important development for our exploration program," said Jason Barnard, President and Chief Executive Officer of Foremost Lithium. "Utilizing aerial drone surveys to better understand the structural details both above and below surface enables us to prioritize the best targets for future drilling. This approach is effective on our large, 43,000-acre district-scale Lithium Lane properties. We look forward to sharing the results from the final LiDAR survey on Peg North once it is completed."

08:42 EDT ASP Isotopes issues letter to shareholders - ASP Isotopes released the following letter to shareholders from its Chairman and CEO, Paul Mann. "At the end of the 3rd quarter, I want to summarize the year-to-date progress and discuss our future goals. We have made significant progress during the first nine months of 2023, completing the construction of our first isotope enrichment plant and signing two supply contracts with North American customers for greater than $11.5 million in expected aggregate revenue for future supply of Carbon-14 and other highly enriched isotopes. In addition, we recently incorporated new subsidiaries in the United States and the United Kingdom to focus on producing HALEU and Lithium-6. These two isotopes are essential to meeting longer-term global climate goals. Our accomplishments during the first nine months of 2023, outlined above, have the potential to generate a substantial amount of free cash flow for the company during 2024... Last week, we announced our strategy to enter the nuclear fuel market with the formation of new U.S. and U.K subsidiaries called Quantum Leap Energy and a Memorandum of Understanding with a leading global Small Modular Reactor Company... We expect to enrich uranium and lithium using our Quantum Enrichment Process, a proprietary technique developed by our scientists to enrich isotopes using lasers... Importantly for ASPI shareholders, our discussions with SMR companies assume that there will be significant financial support in the construction of HALEU production facilities.. It is currently anticipated that the Company will consider plans for a future spin-off of the QLE business to ASPI shareholders so that our shareholders will then benefit from ownership in two entities: ASP Isotopes Inc. and Quantum Leap Energy... The market for isotopes is at an inflection point from both a demand and a supply perspective. We intend to position ASPI and QLE as a trusted supplier of existing isotope products and those of the future."

08:40 EDT Borqs Technologies to expand IoT device businesses in Africa - Borqs Technologies is actively engaged in business development with partners to manufacture smart IoT devices for the African market. The smart IoT devices, mainly mobile phones, will be leased to local users in Africa from a local leasing company. These devices are built with advanced security software to prevent fraud and theft.

08:39 EDT Femasys announces completion of MDSAP surveillance audit - Femasys has completed the annual Medical Device Single Audit Program surveillance audit with no nonconformances and no findings. Femasys currently holds Certificates of Registration for MDSAP from TUV SUD America Inc., a recognized Auditing Organization and Notified Body that conducts a single regulatory audit of medical device manufacturers that satisfies the relevant harmonized regulatory requirements for the countries participating in the MDSAP program, and ISO 13485 Quality System Certification for the commercialization of Femasys products in the U.S., Canada and Japan with the ability to register for market authorization in Australia and Brazil.

08:38 EDT Kineta announces KVA12123 data from Phase 1/2 VISTA-101 trial - Kineta announced an update on its ongoing Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. KVA12123, Kineta's immuno-oncology drug targeting VISTA, cleared the first three monotherapy dose levels and was well tolerated with no dose limiting toxicities or cytokine related adverse events observed. Additionally, KVA12123 exhibited a greater than dose-proportional pharmacokinetic profile achieving greater than 90% VISTA receptor occupancy across patients in the 30 mg dosing cohort. The VISTA-101 trial enrolled 11 patients with advanced solid tumors in the first three monotherapy dose-escalation cohorts, where subjects received either 3, 10 or 30 mg of KVA12123 by intravenous infusion every two weeks. Primary objectives of the Phase 1/2 study are to evaluate the safety and tolerability of KVA12123 and to determine the recommended Phase 2 dose. Patients enrolled in the study were heavily pretreated with multiple prior lines of therapy including chemotherapy, radiation, and immunotherapy. In the first three monotherapy cohorts, KVA12123 was well tolerated at all doses and no DLTs were observed. Furthermore, as KVA12123 was engineered to mitigate adverse events associated with cytokine release syndrome, the study is closely monitoring proinflammatory cytokines that are associated with CRS in the Phase 1 portion of the study. No evidence of CRS or proinflammatory cytokine induction have been observed at any dose level with KVA12123 in the initial cohorts. To guide the RP2D decision, Kineta developed a proprietary assay to evaluate VISTA RO on immune cells from patients treated with KVA12123. Greater than 90% VISTA RO was achieved at the 30 mg dose. Furthermore, pharmacokinetic analyses demonstrated a greater than dose-proportional increase in drug exposure across all evaluated doses, consistent with target-mediated drug disposition at lower doses. Competitive therapies targeting VISTA have demonstrated either poor monotherapy anti-tumor activity in preclinical models or induction of CRS in human clinical trials. Through the combination of unique epitope binding and an optimized IgG1 Fc region, KVA12123 demonstrates strong monotherapy tumor growth inhibition in preclinical models without evidence of CRS in clinical trial participants. KVA12123 effectively de-risks the VISTA target and provides a novel approach to address immune suppression in the TME with a mechanism of action that is differentiated and complementary with T cell focused therapies. KVA12123 may be an effective immunotherapy for many types of cancer including non-small cell lung, colorectal, renal cell carcinoma, head and neck, and ovarian cancer. The company will continue escalating monotherapy dose cohorts of KVA12123 in Part A and initiate Part B of the study to evaluate KVA12123 in combination with pembrolizumab. Initial monotherapy efficacy data are anticipated in Q4 2023 and will be presented, along with safety data, at an upcoming medical conference.

08:37 EDT Oatly Group announces entry into Meijer stores - Oatly Group announced new US retail distribution with Meijer, the family-owned Midwestern retailer known for convenient "one-stop" shopping. Oatly Original and Full Fat 64oz. chilled oatmilks are now available at all 265 Meijer locations, in addition to the Company's 32oz. shelf-stable Original and Barista Edition. "As we continue to grow our retail footprint throughout the US, Meijer represents an important step for us," said Mike Messersmith, President, Oatly North America. "Presence at the beloved Midwestern retailer allows us to introduce our oatmilk products to new customers and new audiences. We're excited for them to try Oatly and experience all the ways our products can be incorporated into their routines - from morning coffee, to cooking recipes, enjoying cereal and more."

08:36 EDT Alexandria Real Estate accelerates delivery of Moderna's new R&D center - Alexandria Real Estate (ARE) has accelerated delivery of 325 Binney Street to Moderna (MRNA). The Class A+ property currently under construction is now set to deliver in November 2023. Located on the Alexandria Center at One Kendall Square mega campus in Cambridge, the facility was selected by Moderna for its new global headquarters and core R&D operations. This development project is also expected to be delivered under budget. As of June 30, the company's highly leased value-creation pipeline is expected to drive future annual incremental NOI aggregating $605M through 2Q26.

08:34 EDT PPL Corp. unit approved to deploy advanced metering functionality - PPL Corp. subsidiary, Rhode Island Energy, has received regulatory approval to deploy advanced metering functionality statewide as the company lays the foundation for a smarter, more resilient, more reliable and more dynamic grid that supports the state's leading climate goals. CEO Sorgi said PPL's experience deploying advanced metering functionality elsewhere will benefit Rhode Island Energy as it rolls out new metering infrastructure. Rhode Island Energy expects to begin installing the next-generation digital meters in late 2024 and to complete the deployment over the next three years. As part of its unanimous decision, the Rhode Island Public Utilities Commission authorized capital investments of up to $153M for this initiative.

08:33 EDT Overstock.com appoints Marcus Lemonis to board of directors - The Board of Directors of Overstock.com (OSTK) has appointed Marcus Lemonis as its newest independent director, effective October 2, 2023. Lemonis is currently the Chairman and CEO of Camping World (CWH).

08:32 EDT Skyward Specialty Insurance, eMaxx expand captives partnership - Skyward Specialty Insurance Group and eMaxx announced the expansion of their captives partnership. Skyward Specialty will provide strategic support and additional capacity for eMaxx's innovative variable Alternative Energy Warranty Products captive solutions. eMaxx's suite of warranty solutions support manufacturers, developers, and owners of renewable, alternative, and energy-efficiency projects by providing an insurance-backed captives solution covering product and performance shortfalls. The partnership will provide the captive participants with access to risk capital and best in class technical engineering-based underwriting and risk management to mitigate performance risk and improve the strength of manufacturer and contractor warranties.

08:30 EDT Alvotech, Kashiv Biosciences enters exclusive licensing agreement for ADL018 - Kashiv Biosciences and Alvotech announced that they have entered into an exclusive licensing agreement for ADL018, a proposed biosimilar to Xolair, which is in clinical development. The agreement covers all 27 countries of the European Union, the UK, Australia, Canada, and New Zealand. Under terms of the agreement, Alvotech will receive an exclusive license to commercialize ADL018, which will be developed and manufactured by Kashiv. Kashiv will receive an upfront payment and is eligible for subsequent milestone payments and royalties.

08:23 EDT Ayro awarded patent for user-tailored vehicle seat fabrication technology - Ayro announces that it has been issued U.S. Patent No. 11752902 from the U.S. Patent and Trademark Office for "Vehicle Seating System and Methods Thereof." The utility patent represents another milestone for AYRO as the Company seeks to develop new innovations in operator-customized seat designs for its vehicles. "AYRO aims to set the standard for sustainability - not an aspirational goal but at the very heart of everything we do, from design and sourcing to manufacturing and vehicle operating parameters," noted Tom Wittenschlaeger, CEO of AYRO. "But achieving true sustainably does not mean sacrificing comfort or aesthetics. This patent is representative of our team's commitment to creating low-speed electric vehicles that are highly functional, sustainable and ideal for a wide range of uses.

08:21 EDT Microchip's Radiation-Tolerant PolarFire FPGA achieves QML Class Q qualification - The company said, "Products that have Qualified Manufacturers List designations are often the most trusted and readily accepted in space program designs. As designated by the Defense Logistics Agency, the RT PolarFire FPGA from Microchip Technology is now QML Class Q qualified. This certification is considered the gold standard in entry-level qualification, enabling designers to begin integrating the RT PolarFire FPGA into their space flight systems more easily. Because QML qualifications are standardized based on specific performance and quality requirements governed by the DLA, customers can streamline their design process by using QML-qualified products."

08:20 EDT Ocean Biomedical announces ability to restore treatment sensitivity Osimertinib - Ocean Biomedical (OCEA) announced that its cancer-targeting immunotherapy antibody candidate has demonstrated effective tumor reduction against an aggressive subset of Non-Small Cell Lung Cancer, NSCLC, with Epidermal Growth Factor Receptor, EGFR, mutations. These research findings generated by Ocean's Scientific Co-founder Dr. Jack A. Elias and colleagues from Yale University and Brown University, and first published as a preprint last week in bioRxiv, are the first to uncover the role of Chitinase 3-like-1 in the pathogenesis of EGFR-mutant cancers, with potential applications not just in NSCLC, but in all EGFR-mutant cancers, including glioblastoma and colon cancer. The studies demonstrate the ability of Ocean Biomedical's cancer-targeting immunotherapeutic antibody to control the growth of human tumor cells with EGFR mutations by suppressing CHI3L1 activity. Additionally, the findings demonstrate a stunning ability to restore therapeutic sensitivity to current tyrosine kinase inhibitor therapies after resistance sets in, including the third-generation TKI, Osimertinib, marketed as Tagrisso by AstraZeneca (AZN). In mouse model testing in combination with Osimertinib, Ocean's antibody was shown to stop human tumor progression by inducing tumor cell death and stimulating tumor suppressor genes. In these findings, the role of CHI3L1 in EGFR-mutant lung cancer is described for the first time. Ocean Biomedical's cancer immunotherapy candidate demonstrates potential use in EGFR-mutant cancer immunotherapy in multiple ways: 1) as a stand-alone therapy 2) as a combination therapy with current TKI inhibitors, and 3) as a "salvage therapy" in combination with TKI inhibitors like Osimertinib-potentially extending their therapeutic life.

08:18 EDT Syneos Health appoints Colin Shannon as CEO - Syneos Health announced that Colin Shannon has been appointed CEO, effective immediately. Shannon succeeds Michelle Keefe, who will continue her tenure with Syneos Health as a key member of the Executive Leadership Team. Shannon and Keefe will remain on the Board of Directors. Shannon brings decades of leadership experience driving growth at global biopharmaceutical solutions organizations. During his 14 years at PRA Health Sciences, Shannon served in executive roles, most recently as Chairman and CEO.

08:16 EDT Lantern Pharma:Data on for LP-184 for GBM published in Clinical Cancer Research - Lantern Pharma announced that in vivo data highlighting the enhanced efficacy of Lantern's drug candidate LP-184 in glioblastoma were published in Clinical Cancer Research, a journal of the American Association for Cancer Research. LP-184 is a unique small molecule with low nanomolar activity and favorable CNS penetration. LP-184 utilizes its powerful mechanism of action, known as synthetic lethality, to exploit common vulnerabilities in solid tumor and CNS cancers with DNA damage repair deficiencies. In addition, Lantern's AI platform, RADR has highlighted overlapping gene dependency profiles between GBM tumorigenesis and sensitivity to LP-184, such as EGFR activation pathways. "The data highlighted in Clinical Cancer Research solidify LP-184 as a promising therapeutic for GBM, with LP-184 having inhibited the viability and growth of multiple GBM models including temozolomide-resistant and MGMT-expressing cells," stated Panna Sharma, Lantern's President and CEO.

08:15 EDT Nokia launches AIMS with Graybar - Nokia announced it is launching Autonomous Inventory Monitoring Service, AIMS, with Graybar, a Fortune 500 company and one of the largest distributors of electrical, communications and data networking products in North America. Nokia AIMS improves the accuracy and efficiency of cycle counting for warehouse operators by using autonomous drones. The drones safely navigate through a warehouse, scanning inventory on shelves, then share up-to-date results and analytics with warehouse managers. Graybar has signed a commercial deal with Nokia using AIMS to enhance its existing inventory management capabilities with this technology. Graybar has also purchased Nokia Digital Automation Cloud to help improve the connectivity in its warehouses.

08:14 EDT MAIA Biotechnology announces FDA clearance of THIO IND application - MAIA Biotechnology announced that the FDA has cleared its Investigational New Drug, or IND, application for THIO to be evaluated in the U.S. as part of THIO-101, the Company's ongoing global phase 2 clinical study in patients with advanced Non-Small Cell Lung Cancer, or NSCLC. THIO is being tested in sequential combination with Regeneron's anti PD-1 monoclonal antibody cemiplimab to evaluate anti-tumor activity and immune response in NSCLC patients.

08:11 EDT Super League Enterprise reports preliminary Q3 revenue $7M, consensus $6.52M - Super League announced preliminary third quarter revenue grew approximately 55% from the year ago comparable period to a record-breaking quarterly revenue level of approximately $7.0 million. Ann Hand, Chief Executive Officer of Super League, commented, "This notable revenue growth is truly a testament of our ability to win over brands aiming to gain traction with the elusive younger audience with an innovative one-stop-shop for virtual worlds. We continue to deliver step change revenue growth with this achievement of record level third quarter 2023 revenue. While the past few months have been incredibly challenging from a capital markets perspective, we have taken the necessary actions to position Super League for a sustainable future. Super League is positioned to benefit from multiple factors including the developing experiential gaming market opportunity, our operating strategy fueled by diverse revenue streams and a healthy pipeline of advertising and publishing partnerships. Recently, company insiders including myself have taken the opportunity to further increase our ownership in Super League to capture the value based upon what we view as a meaningful discount of our share price by the market. Additionally, our shareholder approved 1-for-20 reverse stock split has functioned as appropriate to effectively permit Super League to remain in compliance with the Nasdaq for continued listing on the exchange. We appreciate the support of our shareholders through this process and will continue to closely monitor our good standing while focusing on our capital position and growth objectives."

08:10 EDT Iqvia enters pact with Argenx to provide safety systems, services - Iqvia (IQV) announced a strategic collaboration with Argenx (ARGX) to advance treatment to patients with rare autoimmune diseases through innovative and integrated technology-enabled pharmacovigilance, or PV, safety services and solutions. Iqvia's integrated PV services and technology platforms will support Argenx to enable efficient integration of safety data and adverse event identification and reporting, ultimately facilitating the delivery of new therapies to patients. The integration of safety data, operational processes and business acumen will support argenx to scale its PV and safety organization alongside future company growth. This builds on Iqvia and Argenx's existing collaboration which focuses on the accelerated expansion of clinical development and commercialization of new indications.

08:08 EDT Chegg announces Dana Underwood as Chief Product Officer, effective Oct. 2 - Chegg announced that Dana Underwood has joined the company as Chief Product Officer, effective Oct. 2. In this new role, Dana will be responsible for elevating Chegg's student experience, driving its product execution, and leveraging the power of AI to expand who the company serves and how it serves them. He will also lead the company's learning pathways, research, design, and product management teams, as well as student advocacy.

08:08 EDT Alimera Sciences appoints Jason Werner as COO - Alimera Sciences announced the appointment of Jason Werner, COO, effective October 2, 2023. In conjunction with this appointment, Dr. Philip Ashman, previously Alimera's Chief Operating Officer and Senior Vice President, Commercial Operations Europe, was appointed President of International Operations. Werner has served as a director of Alimera since Q2 2023. Prior to joining Alimera's management team he has served as the Chief Executive Officer and Board Member of SightStream Biotherapeutics.

08:07 EDT Katapult chosen by Casper to expand consumer access to sleep products - Katapult is entering a dynamic new partnership with Casper, the innovative leader in sleep products. Under the terms of the partnership, Casper has integrated Katapult's innovative lease-to-own solution into its payment checkout flow. Casper and Katapult expect this collaboration to unlock purchasing power for many underserved consumers who don't have access to traditional financing options. "We are pleased to join forces with Casper in order to make their durable goods such as mattresses and bedroom furniture more accessible to underserved consumers," said Orlando Zayas, CEO of Katapult. "Our lease-to-own option is an excellent choice for merchants who want to empower the millions of consumers who are routinely overlooked by traditional financing options. We believe that Casper chose Katapult because our track record speaks for itself: we have high net promoter scores and customer repeat purchase rates, demonstrating that consumers who know Katapult - love Katapult. Our mission is to enable consumers to get the durable goods they need and to connect merchant-partners with a growing base of engaged and loyal consumers, and we believe this partnership is another example of how we are bringing our mission to life."

08:07 EDT Essential Utilities to sell three non-utility properties to Cordia for $165M - Essential Utilities announced a binding agreement to sell its three non-utility microgrid and district energy properties in Allegheny County to Cordia, a sustainability-driven energy solutions provider. The agreement is valued at $165M. The agreement covers innovative microgrids and district energy systems developed by Peoples, Essential's gas operations subsidiary based in Pittsburgh, where the assets are located. Essential selected Cordia as the buyer for the three systems in part because of their expertise in microgrids and district energy systems, along with their established footprint in Pittsburgh. Cordia currently operates energy systems in Pittsburgh's Uptown and North Shore neighborhoods, as well as the on-campus energy system for Duquesne University. The company's presence in the region dates back to the 1960s. The sale of these unregulated assets, along with the recently closed West Virginia traction, demonstrate Essential's efforts to focus on its core businesses. The company will continue to prioritize investments in infrastructure to improve safety and reliability, and to reduce emissions.

08:05 EDT NV5 Global awarded $10M Geospatial Forest Resource Management contract - NV5 Global announced that it has been selected by United States Geological Survey for a $10 million contract to perform geospatial lidar data collection and processing of 28,359 square miles in Oregon and Washington state as part of the USGS 3D Elevation Program. The project will support forest resource management and is jointly funded by USGS and the U.S. Forest Service Geospatial Technology and Applications Center of the U.S. Department of Agriculture. The two-year project includes leaf-on lidar data collection in the fall and spring and is expected to be completed in September 2025. "The application of geospatial data in the management of natural resources continues to grow, and we are pleased to support forestry management efforts of the USGS and U.S. Forest Service," said Dickerson Wright, PE, Chairman and CEO of NV5. "NV5 has served the USGS for over 25 years, and we look forward to continuing our support of the USGS' 3DEP mission to achieve high resolution elevation data for all of the United States and its territories."

08:05 EDT Centessa adds April Dovholuk, Ellie Im to senior leadership team - Centessa Pharmaceuticals (CNTA) announced the appointment of April Dovholuk and Ellie Im, MD to Centessa's executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development, Oncology, respectively. In these newly created roles, Ms. Dovholuk will lead both Centessa's global Clinical Trials and Development Operations teams, and Dr. Im will manage clinical development of the Company's Oncology programs based on the LockBody technology platform. Prior to joining Centessa, Ms. Dovholuk was Senior Vice President, Clinical Development Operations at Replimune (REPL). Im most recently served as Senior Vice President, Clinical Development and Operations at Mersana Therapeutics (MRSN).

08:03 EDT UroGen Pharma announces rolling NDA submission for UGN-102 to begin in January - UroGen Pharma announced that it has reached agreement with the FDA on plans for submission of a new drug application, or NDA, for UGN-102 for intravesical solution. The FDA indicated that the current clinical development plan for UGN-102, which includes evaluation of duration of complete response, or CR, at 12 months from the pivotal ENVISION trial, will support submission of an NDA for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer. The FDA also agreed that the UGN-102 NDA can utilize a rolling review, allowing for early submission of the Chemistry, Manufacturing and Controls, or CMC, sections of the NDA, which is planned for January 2024. If approved, UGN-102 has the potential to introduce a new non-surgical treatment paradigm for LG-IR-NMIBC, a subset of bladder cancer patients characterized by high recurrence rates and the need for multiple surgeries. The UGN-102 clinical development plan centers around the Phase 3 ENVISION pivotal trial and is supported by clinical data from the ATLAS Phase 3 and OPTIMA Phase 2b trials.

08:02 EDT Boeing delivers first 777 Freighter to Azerbaijan's Silk Way West airlines - Boeing announced that Silk Way West Airlines' first Boeing 777 Freighter arrived at Heydar Aliyev International Airport. The 777 Freighter will enable Silk Way West to increase its capacity to meet growing cargo demand around the globe. The 777 Freighter will provide Azerbaijan-based Silk Way West with enhanced efficiency and operational flexibility. Founded in 2012 in Baku, Silk Way West Airlines is the largest cargo airline in the Caspian Sea region with an annual cargo turnover of 350,000 tons.

08:01 EDT McCormick down 2% after Q3 results and guidance - Shares of McCormick are down 2% or $1.37 at $73.35 in pre-market trading after the company's in-line Q3 results and updated FY23 guidance.

07:55 EDT Sonder Holdings appoints Adam Bowen Chief Accounting Officer - Sonder Holdings announced the appointment of Adam K. Bowen as Chief Accounting Officer, effective October 9 . Bowen has over 18 years of experience, most recently serving as Vice President & Chief Accounting Officer for BlueLinx Holdings Inc., where he was responsible for the company's record to report functions including consolidations and financial reporting, SEC reporting, corporate tax, financial systems, internal controls, and enterprise risk management.

07:54 EDT Cybin completes dosing in final cohort of CYB003 trial - Cybin announced the completion of dosing of the final cohort in its Phase 2 study of CYB003, a proprietary deuterated psilocybin analog program in development for the potential treatment of major depressive disorder. The CYB003 program is supported by a composition of matter patent with protection through 2041. The company expects to release topline efficacy data in the fourth quarter of this year.

07:53 EDT Welsbach Technology Metals Acquisition announces extension for combination - Welsbach Technology Metals Acquisition Corp. has approved an extension of the time period to consummate a Business Combination, in accordance with Article G of the Company's amended and restated certificate of incorporation, to and including June 30, 2024. On September 29, 2023, the Company held a special meeting of its stockholders. On August 11, 2023, the record date for the special meeting, there were 5,913,698 shares of common stock of the Company entitled to be voted at the special meeting, approximately 84.111% of which were represented in person or by proxy at the special meeting. The final results for each of the matters submitted to a vote of the Company's stockholders at the special meeting are as follows: 1. Charter Amendment Proposal: The stockholders approved the proposal to amend the Company's Charter by allowing the Company to extend the date by which it has to consummate a business combination with a target for up to an additional nine months, from September 30, 2023 to up to June 30, 2024, for no contribution to the trust account. 2. Trust Amendment Proposal: The stockholders approved the proposal to amend the Trust Agreement, allowing the Company to extend the Combination Period for up to an additional nine months, from September 30, 2023 to up to June 30, 2024, for no contribution to the trust account. As there were sufficient votes at the time of the special meeting to approve each of the above proposals, the Adjournment Proposal, which had been previously voted on by proxy, was not presented to stockholders at the special meeting.

07:52 EDT Purple Biotech reports interim, preliminary results from NT219 Phase 1/2 study - Purple Biotech provides clinical updates from its dose escalation portion of the Phase 1/2 study of NT219, a first in class dual inhibitor of Insulin receptor substrate 1/2 and Signal Transducer and Activator of Transcription 3 and provides its outlook for planning the next clinical development steps with NT219 for second-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head & Neck. The Phase 1/2 study, an open-label, dose escalation and expansion study is designed to assess the safety, pharmacokinetics, pharmacodynamics and efficacy of NT219 as a monotherapy and in combination with Erbitux, in patients with R/M SCCHN, or with advanced colorectal cancer. Forty-nine patients were enrolled in five dose levels; 27 in the monotherapy arm, and 22 in the combination therapy with cetuximab. Patients in both cohorts were dosed to the highest NT219 dose level of 50mg/kg. No dose-limiting toxicities were reported in either cohort and NT219 was well tolerated as a monotherapy and in combination with cetuximab. A dose-dependent increase in drug exposure of NT219 was reported. The exposure achieved at the highest dose level of 50mg/kg was within the efficacy range of the human equivalent dose level as predicted from preclinical models. Inhibition of intra-tumoral IRS 1/2 and STAT3, NT219's targets, was demonstrated in patients' biopsies. Among the four R/M SCCHN patients dosed at 50mg/kg of NT219 in combination with cetuximab, that were evaluable for efficacy, two patients demonstrated confirmed partial response by response evaluation criteria in solid tumors 1.1. Other results from the Phase 1/2 study will be provided at one of the upcoming medical conferences. Treatment options for patients who had progressed following treatment with immunotherapy in first line R/M SCCHN are limited, with mostly cetuximab and chemotherapy currently available. The Company is in the process of designing a Phase 2 study of NT219 in combination with cetuximab in 2L R/M SCCHN. Such a study may evaluate NT219 in combination with cetuximab with or without standard of care chemotherapy following progression after immunotherapy in first line treatment.

07:44 EDT Rekor Systems joins AWS ISV Accelerate Program - Rekor Systems has joined the Amazon Web Services Independent Software Vendor Accelerate Program, a co-sell program for AWS Partners who provide proven and well-architected Software-as-a-Service solutions that run on or integrate with AWS. The program helps AWS Partners drive new business by directly connecting participating ISVs with the AWS Sales organization.

07:40 EDT Dragonfly represents battery manufacturing industry during Nevada Trade Mission - Dragonfly Energy Holdings announced that Nevada Governor Joe Lombardo, U.S. and Canadian officials, representatives from Dragonfly Energy, and other select Nevada business leaders recently visited Montreal and Toronto during a Nevada Trade Mission to Canada focused on mining, technology, and green energy storage from September 26-28, 2023. During the trade mission, representatives from Dragonfly Energy explored potential opportunities for collaboration and contributed to meaningful conversations about battery innovation and sustainable energy solutions. Core areas of focus and exploration during the mission included mining, critical minerals, technology, electric vehicles and the battery supply chain.

07:38 EDT Marimed's Betty's Eddies collaborates with Keep A Breast Foundation - Betty's Eddies announced a collaboration with the Keep A Breast Foundation to advance breast cancer awareness education and support the millions of people affected by the disease. The initiative includes redesigned product packaging and a campaign to foster KAB's mission of reducing breast cancer risk through education, with a focus on early detection. Betty's Eddies parent company, MariMed, will also make a monetary donation to KAB. The month-long campaign coincides with Breast Cancer Awareness Month in October.

07:36 EDT Aligos Therapeutics announces award of an $8.5M NIAID contract - Aligos Therapeutics announced that it has been awarded an $8.5 million National Institute of Allergy and Infectious Diseases, NIAID, contract to conduct nonclinical and clinical studies to advance its pan-coronavirus protease inhibitor ALG-097558 into future Phase 2/3 studies. "It is an honor to be awarded this NIAID contract, which is our second NIH-funding received for the development of novel inhibitors of the coronavirus 3CL protease," said Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos Therapeutics. "Given that ALG-097558 potently inhibits all forms of coronavirus tested to date, we believe that this compound will be important for the ongoing COVID-19 endemic as well as for the treatment of emergent novel coronavirus infections in humans in the future. These non-dilutive external funds will enable Aligos to continue to advance the ALG-097558 program beyond the ongoing Phase 1 study, which is evaluating single and multiple doses in healthy volunteers."

07:35 EDT Aurora Technology Acquisition announces additional contribution to trust account - Aurora Technology Acquisition announced its sponsor, ATAC Sponsor, has deposited an aggregate of $135,000 into the Company's trust account in order to extend the date by which the Company has to consummate a business combination from October 9, 2023 to November 9, 2023. The Extension Payment was loaned as a draw down pursuant to an unsecured promissory note the Company issued to the Sponsor on July 31, 2023 with a principal amount equal to $810,000.00. The Extension Note bears no interest and is repayable in full upon the earlier of the date of the consummation of the Company's initial business combination, or the date of the liquidation of the Company, subject to the terms and conditions set forth in the Extension Note. The Company's stockholders are not entitled to vote on or redeem their shares in connection with this extension.

07:33 EDT WK Kellogg announces launch as independent, publicly traded company - WK Kellogg Co (KLG) is celebrating its launch as an independent, publicly traded company with the completion of its planned separation from Kellanova (K), formerly Kellogg Company, on October 2, 2023. The company now trades on the New York Stock Exchange under the ticker symbol "KLG."

07:32 EDT Surge Copper announces assay results from drill holl at Berg Deposit - Surge Copper announced assay results from drill hole BRG23-243, the first hole of the Company's 2023 drilling program testing the deeper portions of the large Berg copper-molybdenum deposit in west-central British Columbia. Highlights: Hole BRG23-243 encountered the second longest mineralized interval from the Berg deposit to date, intersecting 756 metres grading 0.36% copper equivalent from 22 metres depth, with the hole ending in mineralization; The upper portion of the hole encountered the chalcocite blanket returning a subinterval with elevated copper of 172 metres grading 0.35% copper, 0.008% molybdenum, 2.8 g/t silver, and 0.03 g/t gold from 34 metres depth; Hole BRG23-243 was collared in the southeasternmost part of the Berg deposit and demonstrates that the deposit remains open in this direction; Hole BRG23-243 accomplished multiple objectives including learning more about the deep characteristics of the deposit within an area of low drill density, providing material for metallurgical testwork, potentially converting Inferred resources to the Measured and Indicated categories, and extending grade and continuity of mineralization near surface and to depth within the current resource model; Prior to the 2023 program the Berg deposit only had 3 holes with lengths exceeding 600 metres; all 3 holes from the 2023 drill program were longer than 600 metres, and each hole will increase the understanding of Berg mineralization at depth Leif Nilsson, Chief Executive Officer, commented: "We consider hole BRG23-243 to be a tremendous drill result for the Berg project. This was a 100-metre step-out exploration hole that was designed to meet multiple scientific and economic objectives, including extending above-average grades in areas of the current block model with limited drill density, collecting potential sample material for various geochemical and metallurgical tests, and testing the characteristics of an important geological contact within the under-sampled deeper regions of the deposit. The results from the upper portions of the hole demonstrate that the deposit remains open for further expansion to the southeast, with potential implications for future mine optimization and the life of mine strip ratio. The results from the very bottom of the hole, across the contact with and into the Berg Stock, demonstrate the prospectivity of this geological target, which tends to act as a control on stronger molybdenum grades, and has seen very little testing at depth around its entire circumference."

07:31 EDT Enovix announces strategic realignment of Fab1 - Enovix announced that it has initiated a strategic realignment of Fab1 in Fremont designed to refocus the facility from a manufacturing hub to its "Center for Innovation," focused on new product development. This move is supportive of the Company's strategy to locate high-volume manufacturing in Asia near customers and suppliers while locating technology development in both Silicon Valley and Asia. Shifting Fab1's focus will result in a reduction of the workforce in Fremont that had been dedicated to supporting 24/7 manufacturing by approximately 185 personnel, including over 125 contractors. Enovix expects this restructuring to be completed during the fourth quarter of 2023 and result in annualized savings of approximately $22 million. "We do not take these decisions lightly and after careful consideration we determined these changes are necessary to set the company up for long-term success," said Dr. Raj Talluri, President and CEO of Enovix. "It has become clear that Fremont is best positioned to be our Center for Innovation complementing our high-volume manufacturing in Asia." Continued Dr. Talluri, "In addition to these actions, we have re-prioritized our activities in Fab1. We are moving from a horizontal business strategy focused on serving hundreds of customers with a standard-sized battery to a vertical business strategy focused on a smaller group of very large customers who require custom cells, which allows us the most efficient path to scale. This shift has been informed by our strong engagement with leading smartphone OEMs who we anticipate having high volume needs for our battery in 2025 and, in turn, qualification samples in the near-term."

07:20 EDT Laser Photonics finalizes order from Cummins Natural Gas Engines - Laser Photonics finalized an order from Cummins Natural Gas Engines for an LPC-1500-CTHD CleanTech laser blasting system for industrial cleaning and maintenance of their natural gas engines at their New Mexico facility.

07:19 EDT Hyzon Motors ammends intellectual property agreement with Horizon - Hyzon Motors announced an amendment to its Intellectual Property agreement with affiliates of Horizon, Hyzon's majority controlling shareholder and an advanced hydrogen fuel cell solutions company. Under the amendment, Hyzon expands its market access to stationary fuel cell power applications in North America, in addition to its existing access to global fuel cell mobility markets. Stationary fuel cells provide a zero-emission alternative to diesel power generation units used in primary, backup, and off-grid applications. Hyzon is targeting its existing fuel cell IP, production technology, and manufacturing facilities to commercialize stationary products, including near-term demand in end-use applications such as data centers, the entertainment industry, battery electric vehicle charging and remote industrial power needs. The amendment also covers the option for Hyzon and Horizon to pursue joint development of a single stack 300kW fuel cell system, which Hyzon previously announced as part of its product roadmap. Additionally, Hyzon retains rights to the data Horizon gathers across various fuel cell use cases, which is expected to accelerate both companies' real world learnings including around FCEV performance optimization and durability through this collaboration. As amended, the IP agreement will remain in effect until September 2030.

07:17 EDT Solaris Resources appoints CICC as company's Chinese financial advisor - Solaris Resources announces the appointment of China International Capital Corporation Limited, CICC, as the Company's Chinese financial advisor. In recent months, the Company has received a number of proposals from parties interested in acquiring all or part of Solaris' Warintza Project in Ecuador. CICC will assist in fielding and evaluating the merit of these enquiries and other strategic matters.

07:15 EDT Aldebaran Resources reports results from Altar copper-gold project - Aldebaran Resources reports results for all unreported drill holes from the 2022-2023 field campaign at the Altar copper-gold project in San Juan, Argentina. All holes hit mineralization and expanded the mineralized footprint of the Altar project by several hundreds of meters in multiple directions. Planning is currently underway for the 2023-2024 field campaign, with four drill rigs already secured. John Black, Chief Executive Officer of Aldebaran, commented as follows: "We're very excited by the progress that we've made at the Altar project. The recent drill campaign has substantially increased the mineralized footprint of the Altar project and sets us up for an aggressive drill campaign that will begin shortly. The results reported today confirm that the system has a lot of room to grow in several directions."

07:13 EDT Guardian Capital announces termination of Guardian i3 Global REIT ETF - Guardian Capital will terminate Guardian i3 Global REIT ETF effective on or about December 18, 2023. Effective immediately, except in limited circumstances, no further direct subscriptions of units of the ETF will be accepted. Units of the ETF are anticipated to be voluntarily delisted from the Toronto Stock Exchange, at the request of the Manager, and to cease trading, following market close on or about December 15, 2023, with all units still held by investors being subject to a mandatory redemption as of the Termination Date. Unitholders may continue to buy or sell units of the ETF on any stock exchange on which the ETF is traded until the units are delisted. Prior to the Termination Date, the Manager will, to the extent reasonably possible, sell and convert the assets of the ETF to cash. After paying or making adequate provision for the liabilities and obligations of the ETF, the Manager will, as soon as practicable following the Termination Date, distribute the net assets of the ETF pro rata among the unitholders of record on the Termination Date based on the net asset value per unit.

07:12 EDT Regeneron, Intellia expand collaboration for CRISPR-based therapies - Regeneron Pharmaceuticals (REGN) and Intellia Therapeutics (NTLA) announced an expanded research collaboration to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases. This builds on the success of the companies' existing collaboration and continues to combine both companies' deep biology and technology expertise. The collaboration will leverage Regeneron's proprietary antibody-targeted adeno-associated virus vectors and delivery systems and Intellia's proprietary Nme2 CRISPR/Cas9 systems adapted for viral vector delivery and designed to precisely modify a target gene. Under the terms of the expanded agreement, the companies will initially research two in vivo non-liver targets. Intellia will lead the design of the editing methodology and Regeneron will lead the design of the targeted viral vector delivery approach. Each company will have the opportunity to lead potential development and commercialization of product candidates for one target, and the company that is not leading development and commercialization will have the option to enter into a co-development and co-commercialization agreement for the target.

07:10 EDT Xtract One named exclusive preferred supplier of the AAPB - Xtract One Technologies announced the Company will serve as the exclusive preferred supplier for the American Association of Professional Baseball, AAPB. Through this three-year partnership, Xtract One will have the unique ability to advise AAPB regarding security and weapon detection technology, deploy solutions, and ensure best practices to deliver first-class fan experiences. Xtract One's Gateway system replaces traditional metal detectors and hand wands, and delivers fast, reliable, and seamless patron screening. This solution unobtrusively scans patrons for guns, knives, and other prohibited items as they enter the facility, using AI-powered sensors to detect threats without invading patrons' sense of privacy and comfort. "We are thrilled to be partnering with AAPB as their exclusive preferred supplier. We look forward to helping enhance the overall safety for guests at upcoming games, while elevating their game-day experience to a whole new level," said Peter Evans, CEO of Xtract One. "Together with AAPB, we are pleased to be contributing to the vibrant, enjoyable experiences AAPB provides to fans and families."

07:09 EDT Acelyrin appoints Mpofu as Senior Vice President of Development - ACELYRIN announced the appointment of Shephard Mpofu, MD, MRCP, FRCP as Senior Vice President of Development. Dr. Mpofu will be responsible for leading clinical development as well as translational sciences and will also join the company's Senior Leadership Team. Dr. Mpofu joins ACELYRIN after nearly 20 years at Novartis AG, where he most recently served as Chief Medical Officer for its Gene Therapy Franchise.

07:09 EDT RedHill Biopharma's opaganib shows survival benefit in U.S. Army-funded study - RedHill Biopharma announced that novel, twice daily, oral opaganib delivered a statistically significant increase in survival time when given at 150 mg/kg twice a day in a U.S. Army Medical Research Institute of Infectious Diseases in vivo Ebola virus study, making it the first host-directed molecule to show activity in Ebola virus disease. The U.S. Army study tested three doses of opaganib against an inactive vehicle control arm. The in vivo study results showed a statistically significant survival increase in mean survival time of 11.2 days in the 150 mg/kg opaganib group compared to a mean survival time of 5.5 days in the inactive vehicle control group. A 30% mice survival was observed in the 150 mg/kg treated group compared to the vehicle control. Twice daily administered opaganib has previously demonstrated antiviral benefit in late-stage clinical studies of patients hospitalized with moderate to severe COVID-19 and was selected by the NIH Radiation and Nuclear Countermeasures Program for Acute Radiation Syndrome development.

07:08 EDT GXO Logistics announces it is teaming up with Blue Yonder - GXO Logistics announced that it is teaming up with Blue Yonder, a leader in intelligent supply chain software, to deploy a new end-to-end supply chain software solution to power its shared warehousing solution GXO Direct in the U.S. "By leveraging Blue Yonder's solutions, we'll enable customers to add features and customized capabilities on an open WMS platform," said Eduardo Pelleissone, President, Americas and Asia Pacific, GXO. "Customers will now have an agile and cost-effective order management solution with real-time visibility of inventory and orders across all sites. Customers will also have access to value-added services, such as kitting and assembly, to optimize their time and cost to serve. This strengthens our position as a shared warehousing leader as we expand GXO Direct globally."

07:07 EDT PDS announces interim 24-month data from VERSATILE-002 Phase 2 trial of PDS0101 - PDS Biotechnology announced updated interim data based on an August 2nd cut off from the VERSATILE-002 Phase 2 clinical trial evaluating PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA, in patients with unresectable, recurrent, or metastatic HPV16-positive head and neck squamous cell carcinoma, HNSCC. VERSATILE-002 is investigating two patient populations whose cancer has returned or spread - ICI naive and ICI refractory. The ICI naive group had not responded to standard-of-care treatments but had not yet been treated with an ICI. The ICI refractory group included patients who had not responded to multiple prior treatments, including ICI therapy. Data presented at ASCO was based on a January 13th cut off. VERSATILE-002: ICI Naive. Highlights of the interim data from the ICI naive cohort include: 24-month overall survival rate is 74%; published 24-month survival rate of less than 30% for approved ICI; 12-month OS rate is 80%; published results of 30-50% with approved ICIs; Tumor shrinkage seen in 60% of patients; Confirmed overall response rate is 27% to date; Median progression-free survival is 8.1 months to date; published results of 2-3 months PFS with approved ICIs; 13% of patients experienced Grade 3 treatment-related adverse events and 0% experienced Grade 4 or 5 TRAE; published results report 13-17% Grade 3-5 TRAE with approved ICI monotherapy; 60% of patients have CPS score of 1-19, and 40% have CPS score greater than20. VERSATILE-002: ICI Refractory: The goal of this ICI refractory cohort was to confirm and to better understand the role of PDS0101 in prolonging the survival of advanced HPV16-positive head and neck cancer patients who received PDS0101 in combination with KEYTRUDA. This analysis is also intended to provide insight to the contribution of PDS0101 to overall survival in the National Cancer Institute-led study evaluating the combination of PDS0101, PDS0301, and an ICI. Highlights of the interim data from the ICI refractory cohort include: The 12-month OS rate is 56%. The published median 12-month OS rate is 17% with no salvage chemotherapy following tumor progression on ICI; 0% confirmed ORR suggests that PDS0101's impact on survival does not appear to be dependent on tumor shrinkage; 4% of patients experienced Grade 3 TRAE and 0% patients experienced Grade 4 and 5 TRAE.

07:06 EDT AerCap delivers first of eight new Airbus A321neo aircraft to Latam Airlines - AerCap Holdings (AER) announced it has delivered the first of eight new Airbus (EADSY) A321neo aircraft to Latam Airlines Group. The remaining aircraft are scheduled to deliver through 2023 and 2024. The newly delivered aircraft took off from the Airbus Delivery Center in Hamburg, Germany, to Brazil using 49% Sustainable Aviation Fuel.

07:04 EDT Intellia Therapeutics, Regeneron announce expanded research collaboration - Regeneron Pharmaceuticals (REGN) and Intellia Therapeutics (NTLA) announced an expanded research collaboration to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases. This builds on the success of the companies' existing collaboration and continues to combine both companies' deep biology and technology expertise. The collaboration will leverage Regeneron's proprietary antibody-targeted adeno-associated virus vectors and delivery systems and Intellia's proprietary Nme2 CRISPR/Cas9 systems adapted for viral vector delivery and designed to precisely modify a target gene. "We are excited to expand our successful collaboration with Regeneron to now accelerate the development of CRISPR-based therapies outside of the liver for the treatment of neurological and muscular diseases with significant unmet need," said Intellia President and Chief Executive Officer John Leonard, M.D. "At Intellia, we are continuously innovating our editing and delivery solutions to realize the full potential of CRISPR gene editing as a new therapeutic modality. This collaboration is representative of our long-standing belief that the most groundbreaking solutions will come from selecting the best tools for each individual application, all of which are enabled by our industry-leading genome editing toolbox." Under the terms of the expanded agreement, the companies will initially research two in vivo non-liver targets. Intellia will lead the design of the editing methodology and Regeneron will lead the design of the targeted viral vector delivery approach.

07:04 EDT Vontier platform selected by St1 Nordic Oy - Vontier announced that its Driivz platform has been selected by energy company St1 Nordic Oy to manage its growing retail EV charging network. St1 selected Driivz based on the platform's proven track record for reliability as well as its scalability and adoption by companies in the global EV charging industry. The Driivz solution for St1 delivers advanced EV charging operations management for service station chains. The cloud-based platform provides real-time operator dashboards, comprehensive asset management, an automated issue detection and alert system, and proactive problem resolution powered by self-healing algorithms that can address up to 80 percent of productivity and operational problems.

07:03 EDT Medicenna Therapeutics presents preclinical MDNA223 BiSKIT data - Medicenna Therapeutics announced that new preclinical data characterizing MDNA223, an anti-PD1-IL-2 BiSKIT, were presented at the 2023 AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy held from October 1 - 4, 2023, in Toronto, Canada. The poster presentation includes preclinical data demonstrating that the MDNA223 BiSKIT: Showed enhanced IL-2R selectivity and no binding to IL-2R, leading to preferential stimulation of CD8+ T cells over Tregs in human PBMCs, Retained high affinity to PD-1, generating potent blockade of PD-1/PD-L1 mediated exhaustion of T cells, Induced durable proliferation and expansion of CD8+ T cells in the periphery, and enhanced tumor infiltration of functionally active CD8+ T cells, Demonstrated superior efficacy and survival benefit in multiple syngeneic tumor models, including "cold" tumors compared to co-administration of anti-PD1 and IL-2 agonist, Synergized with agonist of the STING pathway to enhance tumor inhibition and promote an abscopal effect as demonstrated by shrinkage of the untreated tumor on opposite flank, Synergized with STING agonist and enhanced tumor inhibition by abscopal effect, Enhanced tumor response while being well-tolerated in a step-up dosing setting.

07:02 EDT RTX chosen by Boeing for X-66A NASA Sustainable Flight Demonstrator project - RTX (RTX) has been selected by Boeing (BA) as a collaborator on the X-66A flight demonstrator, part of NASA's Sustainable Flight Demonstrator project. Two RTX business units, Pratt & Whitney and Collins Aerospace, will support Boeing with Pratt & Whitney GTF engines, and Collins nacelles and engine accessories. Pratt & Whitney and Collins will also support ground and flight tests, slated to start in 2028. The Sustainable Flight Demonstrator is part of NASA's broader Sustainable Flight National Partnership, which is dedicated to developing the technologies needed to achieve net-zero CO2 emissions for commercial aviation. Boeing's X-66A program is focused on developing the Transonic Truss-Braced Wing concept, which could enable significant improvements in fuel efficiency and reduced emissions for next generation single-aisle aircraft.

07:01 EDT OneWater Marine announces strategic relationship with Bradford Marine - OneWater Marine announced that it has entered into a strategic relationship with Bradford Marine, in which OneWater completed a sale/leaseback arrangement of the Roscioli Yachting Center with Bradford Marine to provide world-class support for the OneWater Yacht Group and Sunseeker brands. Concurrently, Bradford Marine will acquire the service operation at the Roscioli Yachting Center and all of the related real estate. The proceeds from this transaction will be used to reduce the Company's long-term debt, as well as fund ongoing strategic M&A opportunities. "This strategic relationship allows us to sharpen our focus on growing our Sunseeker Yacht sales, warranty and service operations, while also strengthening our balance sheet. Roscioli's comprehensive yacht and mega yacht service offering is a natural complement to the highly regarded Bradford family of companies, and we look forward to a continued partnership for years to come," said Austin Singleton, Chief Executive Officer for OneWater.

06:48 EDT Eli Lilly to acquire Point Biopharma for $12.50 per share - Eli Lilly (LLY) and Point Biopharma (PNT) announced a definitive agreement for Lilly to acquire Point. Lilly will commence a tender offer to acquire all outstanding shares of Point for a purchase price of $12.50 per share in cash payable at closing. The transaction has been approved by the boards of directors of both companies. The transaction is not subject to any financing condition and is expected to close near the end of 2023, subject to customary closing conditions, including the tender of a majority of the outstanding shares of Point's common stock, and license transfer approval from the U.S. Nuclear Regulatory Commission. Following the successful closing of the tender offer, Lilly will acquire any shares of Point that are not tendered in the tender offer through a second-step merger at the same consideration as paid in the tender offer. The purchase price payable at closing represents a premium of approximately 87% to Point's closing stock price on October 2, the last trading day before the announcement of the transaction, and 68% to the 30-day volume-weighted average price. Point's board of directors unanimously recommends that Point's stockholders tender their shares in the tender offer. Lilly will determine the accounting treatment of this transaction as a business combination or an asset acquisition, including any related acquired in-process research and development charges, according to Generally Accepted Accounting Principles upon closing. This transaction will thereafter be reflected in Lilly's financial results and financial guidance.

06:47 EDT Brookfield Asset Management raises $12B for global private equity program - Brookfield Asset Management announced the closing of its latest flagship global private equity program, Brookfield Capital Partners VI. With $12B in total capital raised for the strategy, BCP VI is the largest private equity fund raised by Brookfield. Partners in BCP VI are a diverse group of institutional investors, including public and private pension plans, sovereign wealth funds, financial institutions, endowments and foundations, and family offices. Brookfield has committed $3.5B to the Fund, underscoring the firm's alignment of interests with other investors. To date, the Fund has committed approximately $4B to acquire six market-leading businesses and continues to provide meaningful co-investment opportunities to its partners.

06:35 EDT Ault Disruptive Technologies' compliance plan accepted by NYSE - Ault Disruptive Technologies announced that the NYSE American has accepted the company's business plan to regain compliance with the Exchange's continued listing standards. On July 21, the company received notification from the Exchange that it was not in compliance with continued listing standards which require a listed company to maintain a minimum of 200,000 shares publicly held and a minimum of 300 public stockholders on a continuous basis, respectively. The company submitted a plan of compliance to the Exchange on August 18, 2023, addressing how the Company intends to regain compliance with these requirements by December 20, 2024. On September 27, 2023, the company received notice from the Exchange that it had accepted the Plan and granted a plan period through December 20, 2024, to regain compliance with the continued listing standards. If the company is not in compliance with the continued listing standards by that date or if the company does not make progress consistent with the Plan during the plan period, the Exchange may commence delisting procedures.

06:17 EDT WiSA Technologies provides business update - WiSA Technologies provided a business update that focuses on achieving key milestones and reducing total SG&A expenses leading into 2024. CEO Brett Moyer said, "WiSA E development kits began shipping to strategic customers in July 2023, and today we rolled out our licensing plan for WiSA E software, which will drive wireless interoperability between HDTVs, soundbars and speakers. Our strategy is to dominate the link between TV and external audio by eliminating cost redundancy while leveraging this position with other smart devices, and we expect to achieve strategic milestones that provide visibility into multiple customers and revenue streams in 2024...there has been a prolonged challenging industry and capital markets environment. Accordingly, we have initiated expense reductions in SG&A that we expect will lower our cash expenses, albeit while retaining ongoing investments in R&D. The impact of this re-alignment will begin in Q4 2023 and be more fully realized in 2024 as we expect to achieve cash savings of about $0.9M in Q1 2024 and about $4M total in 2024 as compared to 2023. At present, we are prioritizing our WiSA E platform, and we are focused on operational and financial milestones that will demonstrate the platform's efficacy at CES 2024 and believe that our product and strategic refocus coupled with our targeted expense reductions will position us to for an exceptionally productive CES 2025."

06:09 EDT LifeMD and Particle Health report potential of electronic health record data - LifeMD and Particle Health, an intelligent data platform that aggregates and delivers actionable patient data and insights to healthcare companies, announced the results of their joint study demonstrating that delivering actionable clinical insights can save healthcare providers valuable time and streamline the patient weight management journey. The joint research study found that Particle's API platform was able to compliantly review patient health histories collected from electronic health records to contextualize data effectively and efficiently, and potentially facilitate informed decision-making, streamline patient triage and determine eligibility for treatment with Glucagon-Like Peptide-1 drugs. In collaboration with LifeMD, Particle leveraged clinical data to identify those patients with a higher likelihood of meeting the clinical criteria for a GLP-1 drug. The Particle platform's data analysis delivered clinical insights that identified 53% of individuals as requiring a physician touchpoint to acquire more data. As a result of Particle's actionable insights, the patients who were excluded from medication therapy could be redirected to other weight management resources, as appropriate.

06:05 EDT ALX Oncology's evorpacept shows efficacy in Phase 2 gastric cancer trial - ALX Oncology announced positive prespecified interim Phase 2 data from its ASPEN-06 clinical trial, a randomized multi-center international study evaluating evorpacept, the company's CD47 blocking therapeutic, in combination with trastuzumab, Cyramza and paclitaxel for the treatment of patients with HER2-positive gastric/gastroesophageal junction - GEJ - cancer. A confirmed overall response rate of 52% was demonstrated for evorpacept in combination with trastuzumab + Cyramza + paclitaxel compared to 22% for the control group of trastuzumab + Cyramza + paclitaxel. Median duration of response was not reached for the evorpacept combination treatment arm compared to 7.4 months for the control group. The safety profile of evorpacept was consistent with previous clinical trials and was well-tolerated. These interim results compare favorably to the efficacy reported for Cyramza + paclitaxel in the Rainbow study- ORR of 28% and mDOR of 4.4 months -, which is the regulatory benchmark and global standard of care for second line gastric/GEJ cancer. ALX looks forward to reporting the final analysis from the ongoing Phase 2 ASPEN-06 study in Q2 2024 and plans to initiate the Phase 3 portion of ASPEN-06 in late 2024.

06:03 EDT Rockwell Medical enters three-year product purchase agreement with CDC - Rockwell Medical announced that the company entered into a three-year product purchase agreement with Centers for Dialysis Care, the largest non-profit, independent outpatient dialysis provider in Northeast Ohio. CDC provides in-center dialysis, home dialysis, training, education support, and nutrition counseling to individuals with kidney disease and kidney failure. As part of this long-term, multi-million dollar product purchase agreement, which includes supply and purchasing commitments, Rockwell Medical will be the preferred supplier of liquid and dry acid and bicarbonate hemodialysis concentrates and related accessories to CDC and its nearly 20 facilities located throughout Northeastern Ohio.

05:22 EDT Nuvei opens latest operational hub in China - Nuvei announced it has opened its latest operational hub in China as it continues to expand its presence in the Asia-Pacific, or APAC, region. Nuvei is already providing cross-border payment services to many Chinese businesses as they scale internationally, including Geekbuying, Vakatrip, and Cupshe. With its new increased footprint in the region, Nuvei is extending its global reach, as well as servicing current and future clients with an enhanced local expertise and customer service. Launching an office in China is only the latest announcement from Nuvei as it continues to demonstrate its commitment to supporting businesses with accelerating their growth through payments in APAC. Recently, Nuvei announced that it had extended its global reach in the region by obtaining its local acquiring license in Australia, following the announcement that it had obtained local acquiring licenses in Singapore and Hong Kong in 2022. Nuvei also enables businesses in APAC to connect with customers across the region by offering all the relevant alternative payment methods (APMs) to every customer from its suite of 634 APMs.

05:15 EDT Clarivate selected by Yale to provide library services, discovery platforms - Clarivate announced that Yale University has selected Clarivate to provide its library services and discovery platforms. Ex Libris Alma and Ex Libris Primo VE, both part of Clarivate, will provide Yale with a solution that integrates AI and Linked Data to simplify the process for students, researchers and faculty.

05:06 EDT Calliditas Therapeutics partner submits request to MHRA to convert Kinpeygo CMA - Calliditas Therapeutics announced that its partner Stada Arzneimittel has submitted a request to the Medicines and Healthcare products Regulatory Agency, or MHRA, of the United Kingdom to convert the conditional marketing authorization, or CMA, for Kinpeygo, a treatment for primary IgA nephropathy, or IgAN, to standard, or "full", marketing authorization. The submission to the MHRA for full approval, made by Stada's affiliate Britannia Pharmaceuticals, is based on the full two-year data set from the Phase 3 NefIgArd clinical trial, as recently published in leading medical journal The Lancet. The trial met its primary endpoint, with Kinpeygo demonstrating a highly statistically significant benefit over placebo in estimated glomerular filtration rate over the two-year period of nine months of treatment with Kinpeygo or placebo and 15 months of follow-up off drug.